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A B S T R A C T
Background
Foot wounds in people with diabetes mellitus (DM) are a common and serious global health issue. People with DM are prone to
developing foot ulcers and, if these do not heal, they may also undergo foot amputation surgery resulting in postoperative wounds.
Negative pressure wound therapy (NPWT) is a technology that is currently used widely in wound care. NPWT involves the application
of a wound dressing attached to a vacuum suction machine. A carefully controlled negative pressure (or vacuum) sucks wound and
tissue fluid away from the treated area into a canister. A clear and current overview of current evidence is required to facilitate decision-
making regarding its use.
Objectives
To assess the effects of negative pressure wound therapy compared with standard care or other therapies in the treatment of foot wounds
in people with DM in any care setting.
Search methods
In January 2018, for this first update of this review, we searched the Cochrane Wounds Specialised Register; the Cochrane Central
Register of Controlled Trials (CENTRAL); Ovid MEDLINE (including In-Process & Other Non-Indexed Citations); Ovid Embase
and EBSCO CINAHL Plus. We also searched clinical trials registries for ongoing and unpublished studies, and scanned reference
lists of relevant included studies, reviews, meta-analyses and health technology reports to identify additional studies. There were no
restrictions with respect to language, date of publication or study setting. We identified six additional studies for inclusion in the review.
Selection criteria
Published or unpublished randomised controlled trials (RCTs) that evaluated the effects of any brand of NPWT in the treatment of
foot wounds in people with DM, irrespective of date or language of publication. Particular effort was made to identify unpublished
studies.
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Data collection and analysis
Two review authors independently performed study selection, risk of bias assessment and data extraction. Initial disagreements were
resolved by discussion, or by including a third review author when necessary. We presented and analysed data separately for foot ulcers
and postoperative wounds.
Main results
Eleven RCTs (972 participants) met the inclusion criteria. Study sample sizes ranged from 15 to 341 participants. One study had three
arms, which were all included in the review. The remaining 10 studies had two arms. Two studies focused on postamputation wounds
and all other studies included foot ulcers in people with DM. Ten studies compared NPWT with dressings; and one study compared
NPWT delivered at 75 mmHg with NPWT delivered at 125 mmHg. Our primary outcome measures were the number of wounds
healed and time to wound healing.
NPWT compared with dressings for postoperative wounds
Two studies (292 participants) compared NPWT with moist wound dressings in postoperative wounds (postamputation wounds).
Only one study specified a follow-up time, which was 16 weeks. This study (162 participants) reported an increased number of healed
wounds in the NPWT group compared with the dressings group (risk ratio (RR) 1.44, 95% confidence interval (CI) 1.03 to 2.01;
low-certainty evidence, downgraded for risk of bias and imprecision). This study also reported that median time to healing was 21
days shorter with NPWT compared with moist dressings (hazard ratio (HR) calculated by review authors 1.91, 95% CI 1.21 to 2.99;
low-certainty evidence, downgraded for risk of bias and imprecision). Data from the two studies suggest that it is uncertain whether
there is a difference between groups in amputation risk (RR 0.38, 95% CI 0.14 to 1.02; 292 participants; very low-certainty evidence,
downgraded once for risk of bias and twice for imprecision).
NPWT compared with dressings for foot ulcers
There were eight studies (640 participants) in this analysis and follow-up times varied between studies. Six studies (513 participants)
reported the proportion of wounds healed and data could be pooled for five studies. Pooled data (486 participants) suggest that NPWT
may increase the number of healed wounds compared with dressings (RR 1.40, 95% CI 1.14 to 1.72; I² = 0%; low-certainty evidence,
downgraded once for risk of bias and once for imprecision). Three studies assessed time to healing, but only one study reported
usable data. This study reported that NPWT reduced the time to healing compared with dressings (hazard ratio (HR) calculated by
review authors 1.82, 95% CI 1.27 to 2.60; 341 participants; low-certainty evidence, downgraded once for risk of bias and once for
imprecision).
Data from three studies (441 participants) suggest that people allocated to NPWT may be at reduced risk of amputation compared
with people allocated to dressings (RR 0.33, 95% CI 0.15 to 0.70; I² = 0%; low-certainty evidence; downgraded once for risk of bias
and once for imprecision).
Low-pressure compared with high-pressure NPWT for foot ulcers
One study (40 participants) compared NPWT 75 mmHg and NPWT 125 mmHg. Follow-up time was four weeks. There were no
data on primary outcomes. There was no clear difference in the number of wounds closed or covered with surgery between groups
(RR 0.83, 95% CI 0.47 to 1.47; very low-certainty evidence, downgraded once for risk of bias and twice for serious imprecision) and
adverse events (RR 1.50, 95% CI 0.28 to 8.04; very low-certainty evidence, downgraded once for risk of bias and twice for serious
imprecision).
Authors’ conclusions
There is low-certainty evidence to suggest that NPWT, when compared with wound dressings, may increase the proportion of wounds
healed and reduce the time to healing for postoperative foot wounds and ulcers of the foot in people with DM. For the comparisons
of different pressures of NPWT for treating foot ulcers in people with DM, it is uncertain whether there is a difference in the number
of wounds closed or covered with surgery, and adverse events. None of the included studies provided evidence on time to closure or
coverage surgery, health-related quality of life or cost-effectiveness. The limitations in current RCT evidence suggest that further trials
are required to reduce uncertainty around decision-making regarding the use of NPWT to treat foot wounds in people with DM.
P L A I N L A N G U A G E S U M M A R Y
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Negative pressure wound therapy for treating foot wounds in people with diabetes mellitus
What was the aim of this review?
We reviewed the evidence about whether or not negative pressure wound therapy (NPWT) is effective in treating foot wounds in people
with diabetes. Researchers fromCochrane collected and analysed all relevant studies (randomised controlled trials; clinical studies where
people are randomly put into one of two or more treatment groups) to answer this question and found 11 relevant studies.
Key messages
We cannot be certain whether NPWT is effective for treating foot wounds in people with diabetes. There is some low-certainty evidence
that NPWT increases the number of wounds healed compared with dressings, and may reduce the time it takes wounds to heal. We are
uncertain about the effectiveness of different pressures of NPWT on wound healing. Overall, the reliability of the evidence provided
by the trials is too low for us to be certain of the benefits and harms of NPWT for treating foot wounds in people with diabetes.
What did the review study?
Diabetes mellitus is a common condition that leads to high blood glucose (blood sugar) concentrations, with around 2.8 million people
affected in the UK (approximately 4.3% of the population). Some people with diabetes can develop ulcers on their feet. These wounds
can take a long time to heal, they can be painful and become infected. Ulceration of the foot in people with diabetes can also lead to a
higher risk of amputation of parts of the foot or leg. Generally, people with diabetes are at a higher risk of lower-limb amputation than
people without diabetes.
NPWT is a treatment currently being used for wounds including leg ulcers. NPWT involves the application of a wound dressing
attached to a vacuum suction machine which sucks any wound and tissue fluid away from the treated area into a canister. Worldwide,
the use of NPWT is increasing. However, it is expensive compared with wound treatments such as dressings.
We wanted to find out if NPWT could help foot wounds in people with diabetes to heal more quickly and effectively. We wanted to
know if people treated with NPWT experienced any side effects. We were also interested in the impact of NPWT on people’s quality
of life.
What were the main results of the review?
In January 2018, we searched for randomised controlled trials that compared NPWT with other treatments for foot ulcers or other
open wounds of the foot in people with diabetes. We found 11 trials involving 972 adults. Participant numbers in each trial ranged
from 15 to 341 and trial follow-up (observation) times ranged from four weeks to 16 weeks where specified. Not all the studies stated
how they were funded. Two were funded by an NPWT manufacturer.
There is low-certainty evidence to suggest that NPWT may be effective in healing postoperative foot wounds and ulcers of the foot
in people with diabetes compared with wound dressings, in terms of the proportion of wounds healed and time to healing. For the
comparison of different pressures of NPWT for foot ulcers in people with diabetes, we are uncertain whether there is a difference in
the number of wounds closed or covered with surgery, and side effects. There was no evidence available on time to closure or coverage
surgery, health-related quality of life and cost-effectiveness.
How up to date was this review?
We searched for studies that had been published up to January 2018.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
NPWT compared with dressings for postoperative wounds
Patient or population: t reat ing foot wounds in people with diabetes mellitus
Setting: hospital
Intervention: NPWT
Comparison: dressings
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with placebo Risk with NPWT com-
pared with dressings
Proportion of wounds
healed
Follow-up: 16 weeks
Study populat ion RR 1.44
(1.03 to 2.01)
162
(1 study)
⊕⊕©©
Lowa,b
-
388 per 1000 559 per 1000
(400 to 780)
Time to healing
Follow-up: 16 weeks
Study populat ion HR 1.91
(1.21 to 2.99)
162
(1 study)
⊕⊕©©
Lowa,b
-
388 per 1000 609 per 1000
(448 to 770)
Amputations
Follow-up: 16 weeks or
unspecif ied
Study populat ion RR 0.38
(0.14 to 1.02)
292
(2 studies)
⊕©©©
Very lowa,c
-
60 per 1000 23 per 1000
(8 to 61)
Number of wounds
closed or covered with
surgery
954 per 1000 1000 per 1000
(238 to 1000)
RR 1.02
(0.95 to 1.09)
130
(1 study)
⊕©©©
Very lowa,c
-
Adverse events
Follow-up: 16 weeks
Study populat ion RR 0.96
(0.72 to 1.28)
162
(1 study)
⊕©©©
Very lowa,c
-
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541 per 1000 520 per 1000
(390 to 693)
Cost-effectiveness Not est imable Not est imable Not est imable Not est imable Not est imable -
Wound recurrence Not est imable Not est imable Not est imable Not est imable Not est imable -
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; NPWT: negat ive pressure wound therapy; RR: risk rat io.
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded one level due to risk of bias: some blinded outcome assessment, but not sure the potent ial impact of non-
blinded decisions regarding the use of further surgery and the risk of performance bias.
bDowngraded one level due to imprecision: small sample size and wide 95% conf idence intervals.
cDowngraded two levels due to imprecision: few events and 95%conf idence intervals around ef fects included both appreciable
benef it and appreciate harm.
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B A C K G R O U N D
Description of the condition
Diabetes mellitus (DM) is a chronic condition caused by impaired
regulation of blood glucose levels. Normally the hormone insulin
regulates blood glucose, but in people with type 1DMproduction
of insulin no longer occurs. Type 2 DM is characterised by cellular
insensitivity to insulin and reduced insulin secretion. In the UK
approximately 90% of people with DM have type 2 (Diabetes UK
2010).
Worldwide in 2017, there were over 425 million adults with DM
(five million of whom die of the disease annually), and the preva-
lence of diabetes is expected to reach over 640 million (1 in 10) by
2040 (IDF 2017). In the UK adult population, the prevalence of
diagnosed DM is approximately 3.7 million people (Diabetes UK
2017a). In the USA, the 2015 prevalence of diagnosed DM (all
ages) was approximately 9% (CDC 2015), and inCanada in 2008/
2009, for those over one year of age, it was 6.8% (Public Health
Agency of Canada 2011). However, many cases of DM are undi-
agnosed and when these are included, the adjusted 2010 preva-
lence estimates increase to 10.3% for the USA, 9.2% for Canada,
7.8% for India and 10.8% for Mexico. The global prevalence of
DM is projected to rise further up to the late 2030s, largely driven
by ageing populations, obesity and increasingly sedentary lifestyles
(Shaw 2010). Almost half of all deaths attributable to high blood
glucose occur before the age of 70 years and the World Health
Organization (WHO) projects that diabetes will be the seventh
leading cause of death in 2030 (WHO 2016).
DM is a serious health problem because of its associated complica-
tions including microvascular complications such as retinopathy,
nephropathy and neuropathy (damage to the retina, kidney and
nerves); and macrovascular complications including cardiovascu-
lar, cerebrovascular and peripheral arterial disease (PAD). The par-
ticular combination of peripheral neuropathy (nerve damage) and
peripheral vascular disease (damaged veins) contributes to the de-
velopment of foot ulceration, which may lead to surgical debride-
ment or amputation of the foot or lower limb.
Foot wounds in people with diabetes mellitus
There are two main types of foot wounds that can affect people
with DM, foot ulcers and surgical wounds to the foot; these are
summarised below.
Foot ulcers
Both PAD and neuropathy are risk factors for the development of
chronic foot ulceration in people withDM(Pecoraro 1990; Reiber
1999). PAD and neuropathy can occur separately (the ischaemic
foot (PAD) or the neuropathic foot (neuropathy)), or in combi-
nation (the neuroischaemic foot). Foot ulceration is reported to
affect 15% or more of people with DM at some time in their lives
(Reiber 1996; Singh 2005). Estimates of the prevalence of foot
ulceration vary, but around 1% to 4% of people with DM have
foot ulcers at any given time (Abbott 2002; Kumar 1994). Figures
for 2008 showed that, for those people with DM in receipt of US
Medicare, the prevalence of the presence of least one foot ulcer
was 8% (Margolis 2011).
An ulcer forms as a result of damage to the epidermis (outermost
layer of skin) and subsequent loss of underlying tissue. A foot
ulcer is specifically defined by the International Consensus on the
Diabetic Foot as a wound that extends through the full thickness
of the skin below the level of the ankle (Apelqvist 2000a). This
definition is not concerned with duration of the ulcer (although
some definitions of chronic ulceration require a duration of six
weeks or more), and includes ulcers that extend to muscle, tendon
and bone.
The severity of foot ulcers in people with DM can be graded using
a number of systems. TheWagner wound classification systemwas
one of the first described and has, historically, been widely used,
although it is now rarely used in clinical practice. This system as-
sesses ulcer depth and the presence of osteomyelitis (bone infec-
tion) or gangrene and grades ulcers as: grade 0 (pre- or post-ulcera-
tive lesion), grade 1 (partial/full-thickness ulcer), grade 2 (probing
to tendon or capsule), grade 3 (deep with osteitis (inflammation
of the bone)), grade 4 (partial foot gangrene) and grade 5 (whole
foot gangrene) (Wagner 1981). Newer grading systems, such as
the PEDIS system (Schaper 2004), the University of TexasWound
Classification System (Oyibo 2001), and SINBAD (Ince 2008),
have been developed since, with the SINBAD system being the
best validated (Karthikesalingam 2010).
Foot ulcers in people with DM have a serious impact on health-
related quality of life, particularly with respect to physical func-
tioning and role-limitations due to physical and emotional issues
(Nabuurs-Franssen 2005; Ribu 2006). They also represent a ma-
jor use of health resources, incurring costs not only for dressings,
but also staff costs (for podiatrists, nurses, doctors), costs for tests
and investigations, antibiotics and specialist footwear. In 2010 to
2011 the estimated National Health Service (NHS) spend on foot
ulceration and amputation in people with DM in England was
GBP 639 million to GBP 662 million (Diabetes UK 2017b). The
economic impact is also high in terms of the personal costs to
patients and carers, for example, costs associated with lost work
time and productivity while the patient is unable to bear weight
or is hospitalised. As many as 85% of foot-related amputations are
preceded by ulceration (Apelqvist 2000b; Pecoraro 1990).
In terms of ulcer healing, one meta-analysis of trials in which
peoplewith neuropathic ulcers received goodwound care, reported
that 24% of ulcers completely healed by 12 weeks and 31% by 20
weeks (Margolis 1999). Reasons for delayed healing can include:
infection (especially osteomyelitis (bone infection)), comorbidities
such as peripheral vascular disease and end-stage renal disease, and
the size and depth of an ulcer at presentation. Evenwhen ulcers do
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heal, the risk of recurrence is high. Pound 2005 reported that 62%
of people with ulcers (from a sample of 231 people) became ulcer-
free at some stage over a 31-month observation period, however,
40%of the ulcer-free groupwent on to develop a new, or recurrent,
ulcer after a median of 126 days. Indeed, the ulcer recurrence rate
over five years can be as high as 70% (Dorresteijn 2010; Van Gils
1999). Failure of ulcers to heal may result in amputation, and
people with DM have a 10- to 20-fold higher risk of losing a lower
limb, or part of a lower limb, to non-traumatic amputation than
people without DM (Morris 1998; Wrobel 2001).
Surgical wounds to the foot
The risk of lower limb amputation is much greater for people with
DM than for those without. The major underlying pathophys-
iological conditions associated with amputation are neuropathy
and ischaemia. Lower limb amputation can have devastating con-
sequences for people’s health status and health-related quality of
life (Tennvall 2000), as well as having a large financial impact on
healthcare providers and users. In the UK, from 1 April 2007 to
31 March 2010, a total of 16,693 lower limb amputations were
recorded in people with DM (Holman 2012). Of these 10,216
were classed as minor amputations (usually defined as below the
ankle joint), and 6477 as major amputations (usually defined as
above the ankle joint). The cost of diabetic foot care in 2010 to
2011 was estimated at GBP 580 million, almost 0.6% of NHS ex-
penditure in England. Of hospital admissions with recorded dia-
betes, 8.8% included ulcer care (GBP 219 million) or amputation
(GBP 55 million) (Kerr 2014). In the US, the 2008 prevalence of
lower extremity amputation inMedicare recipients was 1.8%,with
a total mean annual Medicare reimbursement cost for each person
with DM and a lower extremity amputation estimated at USD
54,000. Ulcers are often considered to be chronic wounds, while
postsurgical amputation sites are considered to be acute wounds,
unless they do not heal (Ubbink 2008).
As well as amputation, debridement is regarded as an important
component of the treatment of ’chronic’ foot wounds, such as ul-
cers or non-healing surgical wounds, in people with DM, and can
sometimes be undertaken as a surgical procedure.Debridement in-
volves removal of dead tissue and callus, along with pressure-relief/
off-loading, treatment of infection and revascularisation, where
necessary. As in other areas of wound care, sharp (surgical) debride-
ment of diabetic foot wounds is recommended in guidelines in
order to promote wound healing by ’converting’ a chronic wound
to an acute wound via removal of dead tissue and slough (Steed
2006). While this practice is common, there is little evidence that
surgical debridement promotes healing of diabetic foot wounds
(Eneroth 2008; Lebrun 2010), but debridement of necrotic tissue
with eschar from wounds, including diabetic foot wounds, can
sometimes be a requirement prior to the use of wound treatments
such as negative pressure wound therapy (NPWT) (KCI 2018).
Description of the intervention
Any intervention that promotes healing, or reduces amputation
rates, or both, in foot wounds in people with DM would make
an important difference, and a number of health technologies are
marketed as impacting on these outcomes. However, the evidence
for the clinical- and cost-effectiveness of these technologies is fre-
quently lacking. A suite of Cochrane Reviews (Dumville 2011a;
Dumville 2011b;Dumville 2012a;Dumville 2012b), and an asso-
ciated mixed treatment comparison (Dumville 2012c), found no
robust evidence to suggest that any one dressing was more effective
than another in terms of healing foot ulcers in people with DM. A
similar conclusion was drawn following a systematic review by the
International Working Group of the Diabetic Foot (Game 2012).
NPWT is a technology that is currently used widely in wound
care. NPWT is promoted for use on complex wounds, including
foot wounds in people with DM, as an adjunct (additional) ther-
apy to standard care (Guy 2012). NPWT involves the applica-
tion of a wound dressing through which a negative pressure (or
vacuum) is applied, with wound and tissue fluid being collected
into a canister. The intervention was developed in the 1990s, and
the uptake of NPWT in the healthcare systems of high-income
countries has been dramatic. One US Department of Health re-
port estimated that between 2001 and 2007 Medicare payments
for NPWTpumps and associated equipment increased fromUSD
24 million to USD 164 million (an increase of almost 600%)
(Department of Health and Human Services 2009). Initially only
one NPWT manufacturer supplied NPWT machines (the V.A.C
(vacuum-assisted closure) system: Kinetic Concepts Inc (KCI),
San Antonio, TX); however, as theNPWTmarket has grown, sev-
eral different commercial NPWT systems have been developed,
with machines becoming smaller and more portable. Indeed, the
most recent introduction to the market is a single use, or ’dis-
posable,’ negative pressure product. Ad hoc, homemade, negative
pressure devices are also used, especially in resource-poor settings.
These devices tend to use simple wound dressings, such as gauze,
or transparent occlusive (non-permeable) dressings, with negative
pressure generated in hospital by vacuum suction pumps.
Several different healthcare professionals prescribe and apply
NPWT, and it is now used both in secondary and primary (com-
munity) care, particularly following the introduction of ambula-
tory systems. While the NPWT systems outlined above differ in
a number of respects, such as type of pressure (constant or cycli-
cal) applied to the wound, the material in contact with the sur-
face of the wound and also the type of dressing used, the princi-
ple of applying a negative pressure to the wound in a closed en-
vironment is the same for all products. The place of NPWT in
the treatment pathway and the rationale for its use vary based on
different types of wound and local treatment protocols. For open
wounds that have been debrided but are still waiting for soft tissue
cover, National Institute for Health and Care Excellence (NICE)
guidelines recommend that NPWT is considered as an interme-
diate wound dressing prior to further surgical intervention. Thus,
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NPWT would be used for a short period of time on an open,
postsurgical wound, with a key aim of reducing infection risk.
How the intervention might work
NPWT ostensibly assists in wound management by collecting
high volumes of wound exudate, reducing the frequency of dress-
ing changes by keeping anatomically challenging wounds (such
foot wounds) clean, and reducing odour. However, manufacturers
also suggest that the application of mechanical force to the wound
provides biologically plausible processes by which wound healing
is promoted (i.e. the drawing together of wound edges, increased
perfusion, and the removal of infectious material and exudate)
(KCI 2018; Huang 2014). NPWT might have a beneficial effect
by encouraging off-loading (i.e. reducing the weight taken on the
foot, as some NPWT systems make ambulation difficult) and pre-
venting unnecessary dressing changes and repeated exposures to
the environment. The molecular effects of negative pressure on
the wound bed are still being investigated (Glass 2014).
There are some potentially negative aspects associated with
NPWT; these include wound maceration (softening due to expo-
sure to liquid), retention of dressings, and wound infection as well
as other injuries (FDA 2011). NPWT devices are usually worn
continually by patients during treatment, they can interfere with
mobility, and, anecdotally, are often noisy, which prevents some
people from sleeping.
Why it is important to do this review
NPWT is an expensive, yet widely used, health technology for the
management of complex wounds, and there is potential for its use
to increase. In the UK, NPWT can now be prescribed by primary
care physicians (who may not have specific training in wound
care). A Cochrane Review that examined the clinical effectiveness
of NPWT for treating chronic wounds had been previously pub-
lished, but was withdrawn from publication in acknowledgment
of the fact that the topic area was too broad, and that separate
reviews addressing a single wound type (pressure ulcers, venous leg
ulcers and foot ulcers in people with DM) would provide a more
focused summary of evidence. There is a great deal of focus on
the use of NPWT, and it is an area of high research activity and so
is a priority area for review. This updated review includes all foot
wounds in people with DM (both surgical and non-surgical): this
scope means that, for people with DM, we present evidence from
foot wounds caused by surgical debridement and recent amputa-
tion, in addition to evidence for the effects of NPWT on non-sur-
gically treated foot ulcers or other non-healing foot wounds. This
approach provides an up-to-date and comprehensive overview of
evidence for NPWT for all types of foot wound in people with
DM, with a focus on considering the type of diabetic foot wound
to which current evidence relates.
A Cochrane review that comprehensively identifies, interrogates,
presents and synthesises evidence of the effects of NPWT on the
outcomes of foot wounds in people with DM is a valuable piece of
research. The review is relevant to clinical policy and consumer de-
cision-makers in providing a robust overview of current evidence,
and to researchers and funders in highlighting areas of uncertainty
that may be addressed by future research. This is relevant, since
the draft NICE clinical guideline, Diabetic foot problems: preven-
tion and management (NICE 2016), recommends that NPWT is
considered as a treatment after surgical debridement for diabetic
foot ulcers on the advice of the multidisciplinary foot care service.
This is the first update of this review: the update is required since
there are new trials to be added to the review which previously
reported inconclusive findings.
O B J E C T I V E S
To assess the effects of negative pressure wound therapy compared
with standard care or other therapies in the treatment of foot
wounds in people with DM in any care setting.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Published or unpublished randomised controlled trials (RCTs)
that evaluated the effects of any brand of NPWT in the treatment
of foot wounds in people with DM, irrespective of publication
status or language of publication.
Types of participants
Trials recruiting people with type 1 or type 2 DM (as defined by
the study authors), with foot wounds below the ankle, regardless
of underlying aetiology (i.e. ischaemic, neuropathic or neurois-
chaemic). This included diabetic foot ulcers, or wounds result-
ing from amputation or other surgical treatment, or both. We in-
cluded trials involving people of any age and from any setting.
Where trials with broad inclusion criteria recruited people with
DM with foot wounds as part of a larger chronic wound study
population (e.g. alongside participants with pressure ulcers or leg
ulcers), we excluded these trials unless the results for the subgroup
of people with DM with foot wounds were reported separately or
were available from authors on request.
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Types of interventions
Any brand of NPWT (including studies that investigated home-
made or ad hoc negative pressure devices) compared with standard
care (such as advanced wound dressings and gauze) or other treat-
ments, so that the primary intervention of interest was NPWT
(both commercial and non-commercial treatments). We included
RCTs in which the use of a specific NPWT intervention during
the treatment period was the only systematic difference between
treatment groups. We anticipated that likely comparisons would
include the use of NPWT during the care pathway compared
with no use of NPWT or comparison of different types/brands of
NPWT used during the care pathway.
Types of outcome measures
We listed primary and secondary outcomes below. If a study was
otherwise eligible (i.e. correct study design, population and inter-
vention/comparator) but did not report a listed outcome, then we
contacted the study authors where possible to establish whether
an outcome of interest here was measured but not reported. If we
remained unsure whether an outcome was measured or not, the
study was included. We reported outcome measures at the latest
time point available (assumed to be length of follow-up if not
specified) and the time point specified in the methods as being of
primary interest (if this was different from latest time point avail-
able). For all outcomes, we planned to class assessment of outcome
measures from:
• one week or less to eight weeks as short term;
• eight weeks to 16 weeks as medium term;
• more than 16 weeks as long term.
Primary outcomes
• Complete wound healing
◦ Time to wound healing within a specific time period,
correctly analysed using survival, time-to-event, approaches,
ideally with adjustment for relevant covariates such as size of
wound at baseline (start of trial). We assumed that the period of
time in which healing could occur was the duration of the trial,
unless otherwise stated.
◦ Number of wounds completely healed during follow-
up (frequency of complete healing).
Where studies reported both of these outcomes, our plan was to
present all data in a summary outcome table for reference, but give
’time to healing’ primacy. As planned, when time was analysed as
a continuous measure but it was not clear whether all ulcers had
healed,we documented the use of this outcome in the study but did
not summarise, or otherwise use, the data in anymeta-analysis.We
accepted study authors’ definitions of what constituted a healed
wound.
• Amputation
◦ Major amputation (defined as any amputation above
the ankle joint).
◦ Minor amputation (defined as any amputation below
the level of the ankle joint).
Secondary outcomes
• Proportion of wounds closed or covered with surgery:
complete wound closure as the result of delayed surgical closure
but without subsequent wound healing (i.e. the wounds were
surgically closed but not yet healed). The inclusion of this
outcome represents a change from the protocol; see Differences
between protocol and review for more details.
• Time to closure or coverage surgery: NPWT is often not
used until complete wound healing but until a point where the
wound is ready for further treatment such as closure surgery. The
inclusion of this outcome represents a change from the protocol;
see Differences between protocol and review for more details.
• Participant health-related quality of life/health status
(measured using a standardised generic questionnaire such as
EQ-5D, 36-item Short Form (SF-36), 12-item Short Form (SF-
12) or six-item Short Form (SF-6) or wound-specific
questionnaires such as the Cardiff Wound Impact Schedule at
noted time points. These reported data were adjusted for the
baseline score. We did not include ad hoc measures of quality of
life that were not likely to be validated and would not have been
common to multiple trials.
• Other adverse events (measured using survey/questionnaire/
data capture process or visual analogue scale), where a clear
methodology for the collection of adverse event data was
provided. This would include making it clear whether (i) events
were reported at the participant level or if multiple events per
person were reported; and (ii) that an appropriate adjustment
was made for data clustering. Where available, we extracted data
on all serious and all non-serious adverse events. We did not
extract individual types of adverse events such as pain or
infection, which require specific assessment under this outcome,
rather we used the assessment of any event classed as adverse by
the participant or health professional, or both, during the trial.
• Within-trial cost-effectiveness analysis comparing mean
differences in effects with mean cost differences between the two
arms: data extracted were incremental mean cost per incremental
gain in benefit (incremental cost-effectiveness ratio (ICER)). The
inclusion of this outcome represents a change from the protocol;
see Differences between protocol and review for more details.
• Wound recurrence: we accepted study author definitions of
wound recurrence unless it was clear that the term had not been
used to describe the return of a wound that was previously
healed.
Search methods for identification of studies
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Electronic searches
In January 2018, we searched the following electronic databases
to identify reports of relevant clinical trials:
• Cochrane Wounds Group Specialised Register (searched 10
January 2018);
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2017, Issue 12) in the Cochrane Library (searched
10 January 2018);
• Ovid MEDLINE including In-Process & Other Non-
Indexed Citations (1946 to 10 January 2018);
• Ovid Embase (1974 to 10 January 2018);
• EBSCO CINAHL Plus (Cumulative Index to Nursing and
Allied Health Literature; 1937 to 10 January 2018).
Appendix 1 shows the search strategies for the Cochrane Wounds
Specialised Register, CENTRAL,OvidMEDLINE, Ovid Embase
and EBSCO CINAHL Plus. We combined the Ovid MEDLINE
search with the Cochrane Highly Sensitive Search Strategy for
identifying randomised trials in MEDLINE: sensitivity- and pre-
cision-maximising version (2008 revision) ( Lefebvre 2011). We
combined the Embase search with the Ovid Embase filter devel-
oped by theUKCochrane Centre ( Lefebvre 2011).We combined
the CINAHL Plus searches with the trial filters developed by the
Scottish Intercollegiate Guidelines Network (SIGN 2018). There
were no restrictions with respect to language, date of publication
or study setting.
We also searched the following clinical trials registries for unpub-
lished and ongoing studies in the area. We searched for trials eval-
uating NPWT and explored these records for those pertaining to
foot wounds in people with DM as defined above:
• ClinicalTrials.gov ( www.clinicaltrials.gov) (28 February
2018);
• WHO International Clinical Trials Registry Platform (
apps.who.int/trialsearch/Default.aspx) (28 February 2018);
• EU Clinical Trials Register ( www.clinicaltrialsregister.eu/
ctr-search/search) (28 February 2018).
Appendix 1 shows the search strategies for clinical trial registries.
Searching other resources
We aimed to identify other potentially eligible trials or ancillary
publications by searching the reference lists of retrieved included
trials, as well as relevant systematic reviews, meta-analyses and
health technology assessment reports.
When necessary, we contacted authors of key papers and abstracts
to request further information about their trials.
We also examined the content of the European Wound Manage-
ment Association conference proceedings (2012 to 2017) and sys-
tematic reviews in the field that might have referred to data we had
not found, and contacted key manufacturers (KCI, and Smith &
Nephew) to ask about unpublished (as well as ongoing) work.
Data collection and analysis
We carried out data collection and analysis according to methods
stated in the published protocol (Dumville 2013a), which were
based on the Cochrane Handbook for Systematic Reviews of Inter-
ventions (Higgins 2011a).
Selection of studies
Two review authors independently assessed the titles and abstracts
of retrieved studies for relevance. After this initial assessment, we
obtained full copies of all studies considered to be potentially rel-
evant. Two review authors independently checked the full papers
for eligibility; we resolved disagreements by discussion and, where
required, the input of a third review author. We recorded all rea-
sons for exclusion of studies for which we had obtained full copies
in the Characteristics of excluded studies table. We completed a
PRISMA flowchart to summarise this process (Liberati 2009).
Data extraction and management
We extracted and summarised details of the eligible studies using
a data extraction sheet. Two review authors extracted data inde-
pendently and resolved disagreements by discussion, drawing on
a third review author where required. Where data were missing
from reports, we attempted to contact the study authors to ob-
tain this information. We included studies published in duplicate
once, but extracted the maximal amount of data. We extracted the
following data, where possible:
• country of origin;
• participants’ type of DM;
• wound aetiology (e.g. PAD);
• type of wound, including site on foot;
• unit of investigation (per participant) (i.e. single wound, or
foot, or patient, or multiple wounds on the same participant);
• care setting;
• number of participants randomised to each trial arm;
• eligibility criteria and key baseline participant data;
• details of the dressing/treatment regimen received by each
group;
• details of any co interventions;
• number of postamputation/debridement wounds closed
surgically;
• primary and secondary outcome(s) (with definitions);
• outcome data for primary and secondary outcomes (by
group);
• duration of follow-up;
• number of withdrawals (by group);
• adverse events;
• publication status of study; and
• source of funding for trial.
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Assessment of risk of bias in included studies
Two review authors independently assessed each included study
using the Cochrane tool for assessing risk of bias (Higgins 2011a)
(Appendix 2). This tool addresses six specific domains, namely,
sequence generation, allocation concealment, blinding, incom-
plete outcome data, selective outcome reporting and other issues
(e.g. extreme baseline imbalance, issues with unit of investigation).
We assessed blinding of participants and health professionals, and
blinded outcome assessment separately. Blinding to reduce the risk
of performance bias is often not possible in device trials but it can
be minimised, for example, in some cases using blinded panels to
make care decisions. To avoid detection bias, blinded outcome as-
sessment is key in open trials. Hróbjartsson 2012 argued that the
estimated effects of experimental interventions in RCTs tended to
be considerably more optimistic when they were based on non-
blinded assessment of subjective outcomes compared with blinded
assessment.
For our assessment, we were aware that blinding of participants
and health professionals to treatment received would not be pos-
sible, but it was important to understand if, and how, studies had
compensated for this where required. We completed a ’Risk of
bias’ table for each eligible study and resolved disagreements about
risk of bias assessment by discussion. Where possible, when a lack
of reported information resulted in an unclear decision, we con-
tacted authors for clarification.
We classed studies with an assessment of high risk of bias for the
randomisation sequence domain or the allocation concealment
domain or the blinded outcome assessment domain (for specified
outcome) (or a combination of these) as being at overall high
risk of bias. We also considered the potential for performance
and measurement bias for each primary and secondary outcome
extracted.
Measures of treatment effect
Where possible, we grouped studies according to wound type.
Where possible, we presented the outcome results for each trial
with 95% confidence intervals (CI). We reported estimates for
dichotomous outcomes (e.g. ulcers healed during a particular time
period) as risk ratios (RR). We used the RR rather than odds ratio
(OR), since, when event rates are high, as is the case for many
trials reporting wound healing, ORs (when interpreted as RR)
can give an inflated impression of the effect size (Deeks 2002).
We planned to report outcomes relating to continuous data (e.g.
percentage change in ulcer area) as mean differences (MD) and
overall effect size (with 95% CI). Where a study reported data on
time-to-healing (the probability of healing over a consecutive time
period) we planned to report and plot these data (where possible)
using hazard ratio (HR) estimates. However, where the HR was
not reported, but data regarding the number of events and the
P value for a log rank test (reported to at least two significant
figures) were reported, we employedmethods proposed by Parmar
1998 to calculate the HR indirectly. Where log rank test P values
were published to only one significant figure, the robustness of the
calculated HR for the highest possible P value was investigated to
test robustness of estimates.HRs and associated 95%CIswere then
calculated using the inverse variance option in Review Manager 5
(Review Manager 2014).
Unit of analysis issues
We recorded whether trials presented outcomes in relation to a
wound, a foot, a participant or as multiple wounds on the same
participant. We also recorded occasions where multiple wounds
on a participant were (incorrectly) treated as independent within
a study, rather than having within-participant analysis methods
applied.Thiswas recorded as part of the risk of bias assessment. For
wound healing and amputation, unless otherwise stated, where the
number of wounds appeared to equal the number of participants,
we treated the participant as the unit of analysis. For other adverse
event outcomes, in order to facilitate further analyses, we aimed to
establishwhether datawere presented at the level of the participant,
because in this area there is potential for data to refer to multiple
events occurring to a single person (or wound per person), which
means that data cannot be analysed further without violating the
assumption of independence.
Where studies randomised at the participant level and measured
outcomes at the wound level (e.g. wound healing), we treated the
participant as the unit of analysis when the number of wounds
assessed appeared equal to the number of participants (e.g. one
wound per person).
Where there were instances of clustered data, that is where a pro-
portion of individually randomised trial participants had outcome
data collected and reported on multiple wounds, this was not
treated as a cluster trial since not all participants would have mul-
tiple wounds. Rather this was a trial that incorrectly included a
mixture of individual and clustered data. We noted these trials
and recorded the issue in the risk of bias assessment. Data were
extracted and presented but not the subject of any further analyses.
We planned only to incorporate clearly conducted fully clustered
trials into meta-analyses if the trial was analysed correctly. Where
a cluster trial had been conducted but incorrectly analysed, we
recorded this as part of the ’Risk of bias’ assessment. If possible
we planned to approximate the correct analyses based on Cochrane
Handbook for Systematic Reviews of Interventions guidance (Higgins
2011b) using information on:
• the number of clusters (or groups) randomised to each
intervention group; or the average (mean) size of each cluster;
• the outcome data ignoring the cluster design for the total
number of participants (e.g. number or proportion of
participants with events, or means and standard deviations
(SD)); and
• an estimate of the intracluster (or intraclass) correlation
coefficient (ICC).
11Negative pressure wound therapy for treating foot wounds in people with diabetes mellitus (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Where multiple trial arms were reported in a single trial, we
planned to include only the relevant arms. If two interventions or
more interventions were compared with control and eligible for
the same meta-analysis, we planned to pool the intervention arms
and compare them with control. If the study data could not be
analysed correctly, we extracted outcome data and presented them
but did not analysed them further.
Dealing with missing data
It is common to have data missing from trial reports. Exclud-
ing participants post randomisation from the analysis, or ignor-
ing those participants who are lost to follow-up compromises the
randomisation, and potentially introduces bias into the trial. In
individual studies, where data on the proportion of ulcers healed
were presented, we assumed that if randomised participants were
not included in an analysis, their wound did not heal (i.e. they
would be considered in the denominator but not the numerator).
Where a trial did not specify participant group numbers prior to
dropout, we presented only complete-case data. In a time-to-heal-
ing analysis using survival analysis methods, dropouts should be
accounted for as censored data. Hence all participants contributed
to the analysis. Such analysis assumes that dropouts are missing at
random (i.e. not associated with time to healing). We presented
data for area change, and for all secondary outcomes, as a com-
plete-case analysis.
Assessment of heterogeneity
We considered both clinical and statistical heterogeneity. Wher-
ever appropriate, that is, where studies appeared similar in terms
of wound type, intervention type, duration and outcome type, we
pooled data using meta-analysis (conducted using Review Man-
ager 5 (Review Manager 2014)). We planned to assess statistical
heterogeneity using the Chi² test (a significance level of P less than
0.1 was considered to indicate heterogeneity) and the I² estimate
(Higgins 2003). The I² estimate examines the percentage of total
variation across studies due to heterogeneity rather than to chance.
Values of I² higher than 50% indicate a high level of heterogene-
ity. In the absence of clinical heterogeneity and in the presence of
statistical heterogeneity (I² over 50%), we envisioned using a ran-
dom-effects model; however, we did not anticipate pooling studies
where heterogeneity was very high (I² over 75%) (Deeks 2011).
Where there was no clinical or statistical heterogeneity, we used a
fixed-effect model.
Assessment of reporting biases
Reporting biases arise when the dissemination of research findings
is influencedby the nature anddirectionof results. Publication bias
is one of a number of possible causes of small-study effects, that
is, a tendency for estimates of the intervention effect to be more
beneficial in smaller RCTs. Funnel plots allow a visual assessment
of whether small-study effects may be present in a meta-analysis.
A funnel plot is a simple scatter plot of the intervention effect
estimates from individual RCTs against some measure of each
trial’s size or precision (Sterne 2011).We planned to present funnel
plots for meta-analyses comprising 10 RCTs or more using Review
Manager 5 (Review Manager 2014).
Data synthesis
We were unable to pre specify the amount of clinical, method-
ological and statistical heterogeneity in the included studies. Thus,
we used a random-effects approach for meta-analysis. Conducting
meta-analysis with a fixed-effect model in the presence of evenmi-
nor heterogeneity may provide overly narrow CIs. We would only
have used a fixed-effect approach when clinical and methodologi-
cal heterogeneity was assessed to be minimal, and the assumption
that a single underlying treatment effect was being estimated held.
Chi² and I² statistics were used to quantify heterogeneity but were
not used to guide choice ofmodel formeta-analysis (Kontopantelis
2012).We would have exercised caution when meta-analysed data
were at risk of small-study effects because use of a random-effects
model may be unsuitable here. In this case, or where there were
other reasons to question the selection of a fixed-effect or random-
effects model, we planned to assess the impact of the approach us-
ing sensitivity analyses to compare results from alternate models,
but this was not implemented ( Thompson 1999).
We presented data using forest plots where possible. For dichoto-
mous outcomes, we presented the summary estimate as an RR
with 95% CI. Where continuous outcomes were measured, we
presented an MD with 95% CI; we planned to pool standard-
ised mean difference (SMD) estimates where studies measured the
same outcome using different methods. For time-to-event data,
we planned to use the inverse variance method on the estimated
HR and standard error, when reported or calculated from avail-
able data. Unfortunately, it was not possible for us to plot (and, if
appropriate, to pool) estimates of HRs and 95% CIs for time-to-
event data, as there were insufficient data presented in the study
reports. Where time to healing was analysed as a continuous mea-
sure, but it was not clear if all wounds had healed, we documented
use of the outcome in the study, but did not summarise or use
these data in any meta-analysis.
We obtained pooled estimates of the treatment effect using Review
Manager 5 (Review Manager 2014).
Subgroup analysis and investigation of heterogeneity
We considered whether there was potential heterogeneity between
wound dressings used in control groups (i.e. advanced dress-
ings (non-antimicrobial), antimicrobial dressings or basic contact
dressings) as there is no single dressing to suit all scenarios (Wounds
International 2013). Where there was evidence of between-trial
heterogeneity in trial-level co interventions, especially off-loading,
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we envisaged a subgroup analysis being conducted based on vari-
ations in co interventions (e.g. all trial participants reported to re-
ceive adequate off-loading protocol/advice being compared with
trial participants who received unclear advice about off-loading);
however, this was not required. Finally, depending on the number
and heterogeneity of included studies, we considered using meta-
regression to investigate wound aetiology as a possible explanatory
variable but this analysis also was not possible.
Sensitivity analysis
We planned to perform sensitivity analyses to explore the effect of
the removal of studies classed at high risk of bias for any domain,
but this was not possible due to lack of available data.
’Summary of findings’ tables
We used the principles of the GRADE system to assess the cer-
tainty of the body of evidence associated with specific outcomes
(Guyatt 2008), and constructed ’Summary of findings’ tables us-
ing GRADEpro GDT software (GRADEpro GDT 2015).
These tables present key information concerning the certainty of
the evidence, the magnitude of the effects of the interventions
examined and the sum of available data for the main outcomes
(Schünemann 2011a). The ’Summary of findings’ tables also in-
cludes an overall grading of the evidence related to each of the
main outcomes using the GRADE approach, which defines the
certainty of a body of evidence as the extent to which one can be
confident that an estimate of effect or association is close to the true
quantity of specific interest. The certainty of a body of evidence
involves consideration of within-trial risk of bias (methodological
quality), directness of evidence, heterogeneity, precision of effect
estimates and risk of publication bias (Schünemann 2011b). We
included the following main outcomes in the ’Summary of find-
ings’ tables:
• proportion of wounds healed;
• time to ulcer healing;
• amputation;
• number of wounds closed or covered with surgery;
• adverse events;
• cost-effectiveness;
• wound recurrence.
For relevant outcomes reported for comparisons not listed above,
we present a GRADE assessment without a ’Summary of findings’
table.
When evaluating the ’Risk of bias’ domain, we downgraded the
GRADE assessment only when we classified a study as being at
high risk of bias for one or more domains, or when the ’Risk of
bias’ assessment for selection bias was unclear (this was classified
as unclear for the generation of the randomisation sequence do-
main and the allocation concealment domain). We downgraded
the GRADE assessment when the ’Risk of bias’ assessment for
blinding was unclear (this was classified as unclear for the perfor-
mance bias domain and the detection bias domain) as well as at
high risk of bias. We did not downgrade for unclear ’Risk of bias’
assessments in other domains.
We selected an informal optimal information size of 300 for binary
outcomes, following the GRADE default value ( Guyatt 2011).
We also followed GRADE guidance and downgraded twice for
imprecisionwhen therewere very few events andCIs around effects
included both appreciable benefit and appreciable harm.
R E S U L T S
Description of studies
Results of the search
The initial version of this review included five studies (Dumville
2013a). This is the first update and six studies have been added (
Dalla-Paola 2010; Lavery 2014; Nain 2011; Vaidhya 2015; Zhang
2017; Zhu 2014). We present the results of the search in the
PRISMA diagram (Figure 1).
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Figure 1. Study flow diagram (Liberati 2009)
The literature search for this 2018 update yielded 208 abstracts: we
sought 23 full-text articles for further scrutiny. From the 23 arti-
cles, we included six studies. There are no studies awaiting classifi-
cation. See Characteristics of included studies and Characteristics
of excluded studies tables for full details of the studies identi-
fied. We contacted all trial authors for additional information
and missing data; any responses are noted in relevant tables. Four
studies are ongoing: ACTRN12612000885897; ChiCTR-TRC-
12002700; DRKS00000059; and ISRCTN64926597. To date,
only ISRCTN64926597 has begun to recruit participants (see
Ongoing studies).
Included studies
This review includes 11 studies randomising 972 participants. Ten
studies had two arms (Armstrong 2005; Blume 2008; Dalla-Paola
2010; Karatepe 2011; Lavery 2014; Mody 2008; Nain 2011;
Vaidhya 2015; Zhang 2017; Zhu 2014), and one had three arms
(Novinš ak 2010). All studies were parallel studies.
Three studies were undertaken in the USA (Armstrong 2005;
Blume 2008; Lavery 2014); two in China (Zhang 2017; Zhu
2014); one in Italy (Dalla-Paola 2010); one in Croatia (Novinš ak
2010); three in India (Mody 2008; Nain 2011; Vaidhya 2015);
and one in Turkey (Karatepe 2011).
Populations evaluated in the studies were people with DM and
foot wounds resulting from amputation in two studies (Armstrong
2005; Dalla-Paola 2010), and people with DM and foot ulcers in
all the other studies (Blume 2008; Karatepe 2011; Lavery 2014;
Mody 2008; Nain 2011; Novinš ak 2010; Vaidhya 2015; Zhang
2017; Zhu 2014). Two studies reported their funding source:
Armstrong 2005 and Blume 2008 received funding from KCI -
manufacturers of the V.A.C. intervention.
Comparison arms received a variety of treatments including:
• dressings:
◦ advanced moist wound therapy (non-antimicrobial
dressing): Armstrong 2005 (moist wound therapy with alginates,
hydrocolloid, foam or hydrogel dressings); Dalla-Paola 2010
(alginate, hydrofibre, silver-dressing or polyurethanes); Blume
2008 (advanced moist wound therapy dressings, predominantly
hydrogels and alginates);
◦ antimicrobial dressing: Zhang 2017 (0.5% dilute
iodoform gauze and Vaseline gauze); Zhu 2014 (povidone and
lipid dressing);
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◦ basic contact dressing: Karatepe 2011 (sterilised
gauze); Mody 2008 (moist gauze); Nain 2011 (saline moistened
gauze); Novinš ak 2010 (moist dressings and dry gauze);
Vaidhya 2015 (saline moistened gauze);
• different pressures of NPWT: Lavery 2014 (75 mmHg and
125 mmHg).
Trials had a range of follow-up periods:
• four weeks (Lavery 2014);
• eight weeks (Nain 2011; Novinš ak 2010);
• 16 weeks (Armstrong 2005; Blume 2008); or
• unclear (Dalla-Paola 2010; Karatepe 2011; Mody 2008;
Vaidhya 2015; Zhang 2017; Zhu 2014).
In terms of primary outcomes, four studies reported time to heal-
ing data (Armstrong 2005; Blume 2008; Karatepe 2011; Zhu
2014), seven reported proportion of wounds healed (Armstrong
2005; Blume 2008; Mody 2008; Nain 2011; Novinš ak 2010;
Zhang 2017; Zhu 2014); five reported data on amputations
recorded during study follow-up (Armstrong 2005; Blume 2008;
Vaidhya 2015; Zhang 2017; Zhu 2014); and one reported ampu-
tations after the follow-up period (Dalla-Paola 2010). For further
details, see Table 1.
In terms of secondary outcomes, five studies reported number
of wounds closed or covered with surgery (Dalla-Paola 2010;
Lavery 2014;Mody 2008;Vaidhya 2015;Zhu2014), two reported
adverse events (Armstrong 2005; Lavery 2014), and one reported
wound recurrence (Zhu 2014).
Excluded studies
Twenty-eight studies were excluded after investigation of the full
text. Eight studies had study populations with multiple wound
types and we were unable to obtain separate data on people with
DM and foot wounds; nine studies were not considered to be
RCTs; nine studies focused on biochemical and related outcomes
and, due to the very short follow-up, we considered that relevant
outcomes were not measured (they were not reported); and two
studies evaluated NPWT as part of a range of treatments, so this
intervention was not the only difference between trial groups. See
Characteristics of excluded studies for further details.
See Figure 1 for PRISMA diagram.
Risk of bias in included studies
See Figure 2; Figure 3 risk of bias assessment by study.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Adequacy of randomisation process
All included studies were described as ’randomised’ with six studies
providing information to confirm that adequate sequence genera-
tion had taken place (Armstrong 2005; Blume 2008; Dalla-Paola
2010; Karatepe 2011; Lavery 2014; Mody 2008); these were at
low risk of bias for this domain (all studies used computer-gener-
ated sequences). The remaining five studies did not describe how
randomisation took place, and were at unclear risk of bias for this
domain.
Allocation concealment
Two of the 11 studies were low risk of bias for allocation con-
cealment (Armstrong 2005; Blume 2008). Both studies employed
’sealed envelopes containing opaque, black paper labelled with as-
signed treatment and participant ID number that were sequen-
tially numbered and provided to each site,’ which we deemed to
be robust. The remaining studies did not contain enough detail
for us to make a judgement for this domain, and so were at unclear
risk of bias.
Blinding
All studies were at unclear risk of blinding bias. We note that
while Armstrong 2005, Blume 2008, and Lavery 2014 appeared
to undertake some blinded outcome assessment, we questioned
the potential impact of non-blinded decisions regarding the use of
further surgery and the risk of performance bias. There was no in-
dication that the decision to undertake closure or amputation was
guided by the protocol to ensure that there were no differences in
performance between groups for reasons other than the treatment
received (e.g. surgery was an option only when wounds reached
a particular size or condition), or was undertaken by a blinded
committee to ensure consistency between groups. Given the non-
blinded status of health professionals to treatment received, there
may have been the potential for performance bias in promoting
surgery (closure or amputation) in one group compared with the
other.
Incomplete outcome data
Seven studies were at low risk of bias for attrition bias (Armstrong
2005;Dalla-Paola 2010; Lavery 2014;Mody 2008; Vaidhya 2015;
Zhang 2017; Zhu 2014). Three studies were at unclear risk of
bias: Blume 2008 reported a small number of post-randomised
exclusions, as well as being unclear about whether there was a
large number of early censoring in the analysis; Karatepe 2011
and Novinš ak 2010 reported very little information regarding
participant flow through the study. Nain 2011 was at high risk of
bias as it was unclear how many people underwent amputation.
Other potential sources of bias
We assessed Nain 2011 and Novinš ak 2010 as being at unclear
risk of other bias because the data presented in the studies did
not consistently match or lacked clarification, which may have
resulted in bias. We judged Armstrong 2005 and Blume 2008 to
be at unclear risk of bias for this domain as they were funded by
an NPWT manufacturer. All other studies were judged as being
at low risk of bias for this domain.
Effects of interventions
See: Summary of findings for the main comparison NPWT
compared with dressings for postoperative foot wounds in people
with diabetes mellitus; Summary of findings 2NPWTcompared
with dressings for foot ulcers in people with diabetes mellitus;
Summary of findings 3 Low-pressure compared with high-
pressure NPWT for foot ulcers in people with diabetes mellitus
Outcome data are summarised in Table 1.
Postoperative wounds
Comparison 1. Negative pressure wound therapy compared
with dressings
Two studies with 292 participants (medium-term follow-up or
unspecified follow-up) compared NPWTwith dressing for ampu-
tation wounds (Armstrong 2005; Dalla-Paola 2010).
Primary outcome: proportion of wounds healed
One study reported proportion of wounds healed (Armstrong
2005). The study randomised 162 participants with DMwho had
previously undergone foot amputation (to the trans-metatarsal
level) to receiveNPWT(dressing changed every 48 hours) or treat-
ment with alginate, hydrocolloid, foam or hydrogel dressings. Par-
ticipants were followed for 16 weeks. This study reported an in-
creased number of healed wounds in the NPWT group compared
with the dressings group (RR 1.44, 95% CI 1.03 to 2.01; low-
certainty evidence, downgraded once for serious risk of bias and
once for serious imprecision) (Analysis 1.1). This means that peo-
ple in the NPWT group had 1.44 times the ’risk’ (likelihood) of
healing compared with people in the moist dressing group.
In total, 12/77 (22%) participants in the NPWT group had
wounds classed as healed following closure via surgery compared
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with 8/85 (9%) participants in the dressing group. It was not clear
from the report when a surgically closed wound was classed as
healed. We contacted the trial authors and they replied that “sur-
gically closed wounds were classed as healed based on the same
criteria as the open wounds. Epithelialized with no drainage. Typ-
ically that was between 2-4 weeks after closure for both groups
depending on the surgeon’s assessment.”
While participants with ’wounds healed’ did undergo blinded out-
come assessment, health professionals were aware of treatment re-
ceived during the study and could decide to close wounds via
surgery, which risks introducing performance bias into the find-
ings. There was no indication in the study report that this decision
to stop NPWT treatment and recommend surgery was guided
by specific decision rules (e.g. size of wound), or was made in a
blinded fashion. Thus, potentially, different numbers and types of
participants within groups may have had wounds ’closed’.
Primary outcome: time to ulcer healing
One study reported time to healing (complete wound closure)
(Armstrong 2005). The study reported a significantly shorter time
in theNPWTgroup (median time tohealing of 56days) compared
with the moist dressing group (median time to healing 77 days).
Wenoted that these reportedfigures did not agreewith theKaplan-
Meier curve reported in the paper, where median values seemed
to be higher.
The authors reported that the results of the time to wound closure
analysis were statistically significant (P = 0.005: results from a log
rank test). Using the observed numbers of events and total num-
bers in each group together with the reported P value to calculate
the logHR and its standard error (Parmar 1998), we calculated the
log HR to be 0.645 (0.69 where maximum P value of log rank test
assumed, as only reported to one significant figure) with a standard
error of 0.23, which gives an HR of 1.91 (95% CI 1.21 to 2.99).
Thus, our calculations suggest that, at any point during follow-
up, the hazard (or chance) of healing in participants allocated to
NWPT was 1.9 times that of participants allocated to the moist
dressing group; NPWT may decrease the time to healing com-
pared with dressings (low-certainty evidence, downgraded once
for serious risk of bias and once for serious imprecision) (Analysis
1.2). There was the potential for the time to healing outcome to
be biased by the undertaking of closure surgery in a non-blinded
and non-protocol-driven manner.
Primary outcome: amputations
Two studies reported amputation (Armstrong 2005; Dalla-Paola
2010).OnlyDalla-Paola 2010 specifiedmajor andminor amputa-
tions. We decided to carry out meta-analysis without distinguish-
ing between these two subgroups. It is uncertain whether there is
a clear difference between NPWT and wounds treated with dress-
ings in number of amputations ((5/142 (3%) with NPWT versus
14/145 (11%) with dressings; RR 0.38, 95% CI 0.14 to 1.02;
very low-certainty evidence, downgraded once for serious risk of
bias and twice for very serious imprecision) (Analysis 1.3). Ten of
the amputations in the dressing group and three in the NPWT
group were classed as major. Also, it was not clear whether de-
cisions about amputation were covered by decision rules in the
protocol to avoid any potential performance bias.
Secondary outcome: number of wounds closed or covered
with surgery
One study (130 participants) reported data on number of wounds
closed or covered with surgery (Dalla-Paola 2010). Based on the
findings of this single study it is uncertain whether there is a dif-
ference between NPWT or dressings in number of wounds closed
or covered with surgery (RR 1.02, 95% CI 0.95 to 1.09; very low-
certainty evidence, downgraded once for serious risk of bias and
twice for very serious imprecision) (Analysis 1.4).
Secondary outcome: adverse events
One study reported adverse events (Armstrong 2005). From the
study report it is uncertain whether there is a difference in the
number of participants experiencing one or more adverse events in
theNPWTgroup compared with themoist dressing group (40/77
(52%) with NPWT versus 46/85 (54%) with dressings; RR 0.96,
95% CI 0.72 to 1.28; very low-certainty evidence, downgraded
once for serious risk of bias and twice for very serious imprecision)
(Analysis 1.5).
Summary of NPWT compared with wound dressings for
postoperative wounds
Low-certainty evidence reporting the hazard or ’chance’ of healing
over time suggests that there may be a benefit for postoperative
foot wounds in participants with DM being treated with NPWT
compared with dressings. Low-certainty evidence also shows that
NPWTmay decrease the time to healing comparedwith dressings.
There is very low-certainty evidence on number of wounds closed
or covered with surgery, adverse events and amputations, suggest-
ing that it is uncertain whether there is a clear difference between
the treatments (Summary of findings for the main comparison).
Foot ulcers in people with diabetes mellitus
Comparison 2. Negative pressure wound therapy compared
with dressings
Eight studies with 640 participants (medium-term, long-term or
unspecified follow-up) compared NPWT with dressings for foot
ulcers.
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Primary outcome: proportion of wounds healed
Six studies (513 participants; medium-term, long-term or unspec-
ified follow-up) reported proportion of wounds healed (Blume
2008; Mody 2008; Nain 2011; Novinš ak 2010; Zhang 2017;
Zhu 2014). Five studies with 486 participants contributed data
to this comparison (Novinš ak 2010 was not included as actual
numbers of participants healed were not provided) (Analysis 2.1).
Evidence from five pooled studies (n = 486) suggests that NPWT
may increase the number of completely healed wounds compared
with dressings (RR 1.40, 95% CI 1.14 to 1.72; I² = 0%; low-
certainty evidence, downgraded once for serious risk of bias and
once for serious imprecision).
Subgroup analyses
Of the prespecified subgroup analyses, we were only able to con-
duct the comparison based on different wound dressings in con-
trol groups. The results of this analysis are shown in Analysis 2.1.
There is no evidence of a difference between these subgroups (test
for subgroup differences: P = 0.85).
Primary outcome: time to ulcer healing
Three studies (468 participants; long-term or unspecified follow-
up) reported time to ulcer healing data.
Blume 2008 presented a Kaplan-Meier curve and reported that
time to complete wound closure was significantly shorter in the
NPWT group, with median time to healing of 96 days (95% CI
75 to 114), compared with the moist dressing group, in which the
median number of participants healed was not reached over the
16-week follow-up.
A log rank test returned a P value of 0.001. Using the method
recommended in Parmar 1998 we calculated the log HR as 0.598
(0.581 where maximum P value of log rank test assumed as only
reported to one significant figure) with a standard error of 0.182,
which gave an HR of 1.82 (95% CI 1.27 to 2.60). These calcu-
lations suggest that, at any point during follow-up, the hazard (or
chance) of healing for participants allocated to NWPT was 1.8
times that of participants allocated to the moist dressing group.
Using the additional analyses outlined we concluded that NPWT
may decrease the time to healing compared with dressings (low-
certainty evidence, downgraded once for serious risk of bias and
once for serious imprecision). There was potential for the time
to healing outcome to have been affected by the undertaking of
closure surgery in a non-blinded and non-protocol-driven way.
Karatepe 2011 reported that median time to healing was 3.9 weeks
in the NPWT group compared with 4.4 weeks in the gauze group
(P < 0.05, reported by the trial authors) (very low-certainty evi-
dence, downgraded once for serious risk of bias and twice for very
serious imprecision). However, limited data were presented and
an HR could not be calculated.
Zhu 2014 reported themean time to healing of the healedwounds
(mean: 30.32 (SD 3.80) days in the NPWT group compared with
60.51 (SD 8.22) days in the traditional dressing group; P < 0.05,
reported by the trial authors); however, as not all wounds healed
in this study, it was not appropriate to further analyse mean time
to healing data (very low-certainty evidence, downgraded once for
serious risk of bias and twice for very serious imprecision).
We did not pool data for this comparison as we were unable to
convert all results into a single suitable measure with associated
variance measures.
Primary outcome: amputations
Three studies (441 participants; long-term or unspecified follow-
up) reported amputation (without distinguishing between major
and minor amputations) (Blume 2008; Zhang 2017; Zhu 2014).
The pooled study evidence suggests that NPWT may decrease
amputations compared with dressings (RR 0.33, 95% CI 0.15
to 0.70; I² = 0%; low-certainty evidence, downgraded once for
serious risk of bias and once for serious imprecision) (Analysis 2.2).
A fourth study reported data for alternative therapy or amputation
(which we reported narratively rather than pooling them into an
analysis; 3/30 participants with NPWT versus 7/30 participants
with control) (Vaidhya 2015).
The other four studies did not report relevant data about amputa-
tion (Karatepe 2011; Mody 2008; Nain 2011; Novinš ak 2010).
Secondary outcome: number of wounds closed or covered
with surgery
Three studies (129 participants; unspecified follow-up) reported
number of wounds closed or covered with surgery (Mody 2008;
Vaidhya 2015; Zhu 2014). The pooled study evidence suggests
there is no clear difference between NPWT and dressing-treated
wounds in number of wounds closed or covered with surgery (RR
1.02, 95% CI 0.85 to 1.24; I² = 28%; low-certainty evidence,
downgraded once for serious risk of bias and once for serious
imprecision) (Analysis 2.3).
Secondary outcome: wound recurrence
One study (60 participants; long-term follow-up) reported data on
wound recurrence (Zhu 2014). The reported duration of follow-
up was six to 10 months. Based on the findings of this single
study we are uncertain whether NPWT reduces the risk of wound
recurrence compared with dressings (RR 0.50, 95% CI 0.10 to
2.53; very low-certainty evidence, downgraded once for serious
risk of bias and twice due to very serious imprecision) (Analysis
2.4).
Summary of NPWT compared with wound dressings for foot
ulcers
Available trial evidence from five studies with 486 participants
shows that NPWTmay increase the number of completely healed
wounds compared with dressings (low-certainty evidence). Data
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from one study (342 participants) suggests that NPWT may de-
crease the time to healing compared with dressings (low-certainty
evidence). Data from three studies (441 participants) suggests
treatment with NPWT may reduce the risk of amputation com-
pared with dressings (low-certainty evidence). Data from three
studies (129 participants) shows no clear difference in number of
wounds closed or covered with surgery (low-certainty evidence).
It is uncertain whether the incidence of wound recurrence differed
between groups (very low-certainty evidence from one study with
60 participants) (Summary of findings 2).
Comparison 3. NPWT 75 mmHg versus 125 mmHg
One study (40 participants, short-term follow-up) compared
NPWT 75 mmHg versus 125 mmHg (Lavery 2014). The study
randomised 40 people withDMwith foot ulcers to receiveNPWT
75 mmHg or NPWT 125 mmHg. Participants were followed-up
for four weeks.
Primary outcome: proportion of wounds healed
The study did not report proportion of wounds healed.
Primary outcome: time to ulcer healing
The study did not report time to ulcer healing.
Primary outcome: amputations
The study did not report amputations.
Secondary outcome: number of wounds closed or covered
with surgery
Based on the findings of this single study we are uncertain whether
there is a difference between NPWT 75 mmHg and NPWT 125
mmHg in terms of the number of wounds closed or covered with
surgery (RR 0.83, 95% CI 0.47 to 1.47; very low-certainty evi-
dence, downgraded once for serious risk of bias and twice for very
serious imprecision) (Analysis 3.1).
Secondary outcome: adverse events
Based on the findings of this single study we are uncertain whether
there is a difference between NPWT 75 mmHg and NPWT 125
mmHg in terms of number of adverse events (RR 1.50, 95% CI
0.28 to 8.04; very low-certainty evidence, downgraded once for
serious risk of bias and twice for very serious imprecision) (Analysis
3.2).
Summary of low compared with high pressure of NPWT for
diabetic foot ulcers
It is uncertain whether there is a difference in the number of
wounds closed or covered with surgery and adverse events between
NPWT 75 mmHg or NPWT 125 mmHg groups (very low-cer-
tainty evidence; Summary of findings 3). There were no data on
primary outcomes.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
NPWT compared with dressings for diabetic foot ulcers
Patient or population: t reat ing foot wounds in people with diabetes mellitus
Setting: hospital
Intervention: NPWT
Comparison: dressings
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with placebo Risk with NPWT com-
pared with dressings
Proportion of wounds
healed
Follow-up: unclear for 4
studies and 8-16 weeks
for the other 3 studies
Study populat ion RR 1.40
(1.14 to 1.72)
486
(5 studies)
⊕⊕©©
Lowa,b
-
406 per 1000 540 per 1000
(475 to 617)
Time to healing
Follow-up: unclear for 2
studies and 16 weeks
for the other study
Study populat ion - 468
(3 studies)
⊕⊕©©
Lowa,b
3 studies reported HR,
median and mean (1
each) and we were un-
able to pool any data
for this comparisonSee comment See comment
Amputations
Follow-up: unclear for 4
studies and 16 weeks
for the other study
Study populat ion RR 0.33
(0.15 to 0.70)
441
(3 studies)
⊕⊕©©
Lowa,b
-
114 per 1000 38 per 1000
(17 to 80)
Number of wounds
closed or covered with
surgery
Follow-up: unclear
Study populat ion RR 1.02
(0.85 to 1.24)
129
(3 studies)
⊕⊕©©
Lowa,b
-
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714 per 1000 729 per 1000
(607 to 886)
Adverse events Not est imable Not est imable Not est imable Not est imable Not est imable -
Cost-effectiveness Not est imable Not est imable Not est imable Not est imable Not est imable -
Wound recurrence
Follow-up: 6-10 months
Study populat ion RR 0.50
(0.10 to 2.53)
60
(1 study)
⊕©©©
Very lowa,c
-
133 per 1000 66 per 1000
(12 to 297)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; NPWT: negat ive pressure wound therapy; HR: hazard rat io; RR: risk rat io.
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded one level due to risk of bias (no blind outcome assessment).
bDowngraded one level due to imprecision: small sample size and wide 95% conf idence intervals.
cDowngraded two levels due to very serious Imprecision.
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Low-pressure compared with high-pressure NPWT for diabetic foot ulcers
Patient or population: t reat ing foot wounds in people with diabetes mellitus
Setting: hospital
Intervention: low-pressure NPWT (75 mmHg)
Comparison: high-pressure NPWT (125 mmHg)
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with placebo Risk with low compared
with high pressure of
NPWT
Proportion of wounds
healed
Not est imable Not est imable Not est imable Not est imable Not est imable -
Time to ulcer healing Not est imable Not est imable Not est imable Not est imable Not est imable -
Amputation Not est imable Not est imable Not est imable Not est imable Not est imable -
Number of wounds
closed or covered with
surgery
Follow-up: 4 weeks
Study populat ion RR 0.83
(0.47 to 1.47)
40
(1 study)
⊕©©©
Very lowa
-
600 per 1000 498 per 1000
(282 to 882)
Adverse events
Follow-up: 4 weeks
Study populat ion RR 1.50
(0.28 to 8.04)
40
(1 study)
⊕©©©
Very lowa
-
100 per 1000 150 per 1000
(28 to 804)
Cost-effectiveness Not est imable Not est imable Not est imable Not est imable Not est imable -
Wound recurrence Not est imable Not est imable Not est imable Not est imable Not est imable -
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*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; NPWT: negat ive pressure wound therapy; RR: risk rat io.
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded three levels: once for risk of bias (some blinded outcome assessment, but not sure the potent ial impact of non-
blinded decisions regarding the use of further surgery and the risk of performance bias); twice for very serious imprecision
with a small sample size and lim ited reported information to quant if y imprecision.
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D I S C U S S I O N
See: Summary of findings for the main comparison; Summary of
findings 2; Summary of findings 3.
Summary of main results
We included 11 studies with 972 participants in the review. Ten
studies compared NPWT with dressings (two for amputation
wounds and eight for foot ulcers in people with DM); one study
compared NPWT at 75 mmHg and 125mmHg for the treatment
of foot ulcers.
NPWT compared with dressings in postoperative
wounds
There is low-certainty evidence to suggest that NPWT may be
effective in healing postoperative foot wounds compared with
wound dressings in terms of the proportion of wounds healed and
time to healing. It is uncertain whether there is a difference in
number of wounds closed or covered with surgery, adverse events
and amputations between the treatment groups (very low-certainty
evidence).
NPWT compared with dressings in diabetic foot
ulcers
There is low-certainty evidence to suggest that NPWT may be
effective in healing ulcers comparedwith wound dressings in terms
of the proportion of wounds healed and time to healing. There
is low-certainty evidence suggesting NPWT may reduce the risk
of amputation, but that there is no clear difference in the number
of wounds closed or covered with surgery between the treatment
groups. It is uncertain whether the incidence of wound recurrence
differs between groups (very low-certainty evidence).
Low compared with high pressure NPWT in diabetic
foot ulcers
It is uncertain whether there is a difference in number of wounds
closed or covered with surgery and adverse events between treat-
ment with NPWT 75 mmHg or NPWT 125 mmHg (very low-
certainty evidence). There were no data on primary outcomes.
Overall completeness and applicability of
evidence
The included studies recruited adults with DM with foot wounds
involving postoperative amputation wounds and foot ulcers. The
included studies compared NPWT with dressings and compared
NPWTapplied at different pressures for treatingmultiplewounds.
Althoughwe identified 11 studies, many of these did not report, or
did not fully report, the primary outcomes of this review: wound
healing and amputation. Therefore, usable data on key outcomes
were limited and often unavailable. Only a minority of studies re-
ported enough data to enable us to calculate the most appropriate
measure of time-to-event data - an HR. Where this was not avail-
able, we were in some cases able to report a mean time to healing
or a relative risk of healing for a particular time point. Neither of
these measures was ideal and both may have given an impression
of either an effect or a lack of effect which was not truly present,
particularly where the event rate was high. For the secondary out-
comes, apart from the number of wounds closed or covered with
surgery and adverse events, the other outcomes were reported in
single studies. All evidence is of low or very low certainty because
of risk of bias and imprecision.
The included studies took place in a range of settings and coun-
tries, including low- to middle-income countries. The geograph-
ical distribution of the studies reflected the concentration of dis-
ease burden outside of Western high-income countries. The use
of NPWT for the treatment of foot wounds in people with DM
was similar in that the treatment was used on the most serious
wounds that could not be easily covered or closed during initial
surgery. The treatment aim inmost studies was to close the wounds
in the near future, which seemed to reflect common practice in
this area. Beyond this, treatment protocol varied across studies in
terms of frequency of dressing change and dressing type; however,
these variations are common in clinical practice. We grouped all
dressing treatments as one control group, which we acknowledge
is a broad grouping. The generalisability from such a grouping is
unclear and the evidence will need to be considered alongside the
results of further studies when these become available.
Quality of the evidence
The certainty of the available evidence is low or very low. This is
due to the risk of bias, small sample size and wide CIs that in-
cluded both an effect and no effect or even a harm of the interven-
tion. We downgraded the evidence certainty due to the high risk
of bias for the randomisation sequence domain or the allocation
concealment domain or the blinded outcome assessment domain
or a combination of these. We also downgraded the evidence cer-
tainty if the randomisation sequence domain and the allocation
concealment domain were both at unclear risk of bias; similarly,
we downgraded the evidence certainty if the performance bias and
detection bias were both assessed as unclear risk of bias.
We noted that while Armstrong 2005, Blume 2008, and Lavery
2014 appeared to undertake some blinded outcome assessment,
we questioned the potential impact of non-blinded decisions re-
garding the use of further surgery and the increased risk of perfor-
mance bias. Given the non-blinded status of health professionals
to treatment received, theremay have been the potential for perfor-
mance bias in promoting surgery (closure or amputation) in one
group compared with the other. The two largest studies included
in this review, Armstrong 2005 and Blume 2008, were similar in
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design (both were funded by themanufacturer of V.A.C., i.e. KCI)
although they evaluated different types of foot wounds. While
these studies were deemed to be at low risk of bias for random se-
quence generation and allocation concealment, the risk of perfor-
mance and detection bias for both was unclear, since study reports
suggested that key decisions regarding the treatment of wounds,
such as closure surgery and further amputation, were made by un-
blinded health professionals and were not guided by a trial pro-
tocol in a way that would minimise potential performance bias.
This issue has been noted in other reviews (e.g. Medical Advisory
Secretariat 2006), and the validity of combining wounds closed
by secondary intention and those closed by surgery questioned.
For Blume 2008, it was also unclear whether the study’s analysis
was as close to an intention-to-treat analysis as would be possible
with the data collected. The sample sizes of the remaining studies
were quite small, leading to imprecision and wide CIs; which in
turn led to an overall assessment of very low-certainty evidence.
We also noted that the included studies had limited information
about the receipt of important adjunctive therapies such as off-
loading. While these therapies were often noted as being delivered
where required, it would be useful to know whether their delivery
was balanced between study groups, as they are such an important
part of routine care.
Potential biases in the review process
Following the upgrade of Review Manager 5 in recent years, new
methods which were not previously considered were subsequently
included in the review. These changes have been highlighted in
the Differences between protocol and review section. These addi-
tions only serve to ensure a more robust process and methodology;
therefore, we do not consider them to be of concern.
We made a concerted effort to prevent biases during the review
process by ensuring an extensive literature search and strict ad-
herence to the published protocol. In this, as in other areas, all
RCT data should be available in the public domain to enable deci-
sion-making to be informed by the most comprehensive evidence
base possible. However, previous work highlighted the large num-
ber of RCTs of NPWT that have either been terminated, or have
been completed but remain unpublished (Peinemann 2008). Ex-
tensive searching here did not locate further unpublished studies
beyond those previously identified (Peinemann 2008). However,
there may well be other studies of which we are not aware. We
also noted that some studies were excluded because they evaluated
interventions on multiple wound types, and specific data for foot
wounds in people with DM were not available.
The protocol was not specific with regard to wound closure by
surgery; we made a decision in this update to include the number
of wounds closed or covered with surgery and time to closure or
coverage surgery as secondary outcomes. Changing the outcomes
of a review is often a potential source of bias. However, wound
closure by surgery is a clinically important outcome and the fact
that it was not included in the protocol represented an oversight
on our part. The inclusion of the outcomes in the review was not
driven by the data available in the included studies. We also made
a decision to include cost effectiveness rather than resource use as
a secondary outcome, in view of the importance of this in deter-
mining the implementation of relatively high-cost interventions
such as NPWT.
Agreements and disagreements with other
studies or reviews
We found one systematic review that evaluated the clinical efficacy
of NPWT in treating foot ulcers in people with DM (Liu 2017 -
no relation to this Cochrane Review author). There was some over-
lap between this review and our Cochrane Review. The review in-
cluded 11 studies that were classed as RCTs, however we excluded
two of these studies (McCallon 2000, 10 participants; Sun 2007,
38 participants), as they used alternation and four further studies
did notmeasure relevant outcome data (Eginton 2003; Sajid 2015;
and Sun 2007 measured change in size data and Sepulveda 2009
measured granulation data). Liu 2017 highlighted the positive
findings in complete ulcer healing from Armstrong 2005; Blume
2008; Karatepe 2011; Nain 2011; Vaidhya 2015; and McCallon
2000. Liu 2017 also highlighted the positive findings in reducing
amputation from Armstrong 2005; and Blume 2008. However,
Liu 2017 did not conduct a GRADE assessment, so while our
review drew similar conclusions, we included an additional six
RCTs and used GRADE assessment to highlight the low certainty
in many findings due to risk of bias and imprecision. Addition-
ally, there were also differences between reviews in the analytical
approaches taken. This Cochrane Review contains HRs derived
from reported data to allow evaluation of the ’chance’ of healing
over time for some of the comparisons; this is a more robust mea-
sure of the outcome than mean time to healing or the occurrence
of healing events at a single time point.
We found another systematic review with a title suggesting a focus
on foot ulcers in people with DM (Noble-Bell 2008). The review
included four studies that were classed as RCTs; however, we ex-
cluded two of these from our review (Etoz 2007, 24 participants;
McCallon 2000, 10 participants), as they used alternation and
we considered this a quasi-randomised method of allocation. We
excluded the third study from our review as it did not measure
relevant outcome data (Eginton 2003). We included the fourth
study in our review (Armstrong 2005). The Noble-Bell 2008 re-
viewhighlighted the positive findings fromArmstrong 2005,while
recommending further larger RCTs in a wider number of diabetic
foot-wound groups. We summarised the same RCT findings, but
recommend more cautious interpretation of Armstrong 2005.
Finally, NICE guidelines reviewed the data regarding use of
NPWT for treatment of foot wounds in people with DM (NICE
2016). They included three studies: two of which we included
here (Armstrong 2005; Blume 2008), and one which we excluded
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(as above; Etoz 2007). The review conducted within the guideline
also found that “two RCTs with a total number of 497 partici-
pants showed that participants who received NPWT with stan-
dard wound care were significantly less likely to have an amputa-
tion, and significantly more likely to have complete wound clo-
sure, when compared with participants who received standard
wound care alone.” However, the GRADE assessment of the evi-
dence in theNICE guideline regarded this as low-quality evidence.
The NICE Guideline Development Group recommended that,
“a health economic evaluation should be carried out to further
assess its [NPWT] cost effectiveness as an adjunctive treatment
for diabetic foot problems.” The Guideline Development Group
also “recommended the use of the intervention in the context of a
clinical trial or as a rescue therapy to prevent amputation” (NICE
2016). The findings from our review agreed that further robust
RCT research would help to reduce uncertainty regarding the ef-
fectiveness of NPWT in the treatment of foot wounds in people
with DM. Robust studies should focus on ensuring confidence
that differences in outcomes, such as healing and amputations,
can be attributed to the intervention, rather than occurring as a
result of bias.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review draws together all relevant studies that evaluated neg-
ative pressure wound therapy (NPWT) for the treatment of foot
wounds in people with diabetes mellitus (DM). The robust review
process considered only randomised controlled trials (RCTs), ex-
cluding studies that indicated that participants had been allocated
using alternation.
Data from several RCTs, including the two largest studies, suggest
thatNPWTmay be an effective treatment (including ulcer healing
and amputation) compared with dressings in terms of healing de-
brided foot ulcers and postoperative amputation wounds in people
with DM.However, we graded the evidence for these comparisons
as low or very low certainty since the included studies could be at
risk of bias. The effect of different NPWT treatments (different
pressure and pathways) in many of the comparisons is unclear: it is
often uncertain whether there is any difference in healing, wound
closure, adverse events or other outcomes. The certainty of the
evidence is very low, primarily due to the high levels of impreci-
sion around the estimates of effect. Thus, any potential change in
practice regarding the use of NPWT would need to be informed
by clinical experience and acknowledge the uncertainty around
this decision due to the quality of data.
Implications for research
There is a lack of high-quality evidence on the effect of NPWT
on foot wounds in people with DM. Given that several RCTs of
NPWT for foot wounds and other wound types are underway,
decision makers and funders need to assess the relative priority of
this research question compared with others in wound care. There
is scope for future research in this area - probably large robust
RCTs. Given the importance of wound healing, any future studies
should, alongside standard areas of good practice:
• have appropriate follow-up times to capture maximal
information about important outcomes such as time-to-healing
and amputations (e.g. 12 months);
• collect and report detailed adverse event data;
• collect and report health-related quality of life data using
validated measures;
• collect and report cost-effectiveness data;
• ensure protocols are designed to minimise the potential for
performance bias.
Additionally, time to event measures (time to healing or time to
closure or coverage surgery) are very important inwounds research.
When time is analysed as a continuous measure (mean time to
healing), this is only a valid time to event measure if it is clear
that all wounds have healed/closed by surgery (i.e. had the event
of interest) - otherwise by default it is not possible to calculate
a mean value. Any future studies should clarify this point when
reporting the mean time to healing/closure or coverage surgery or
use median measures.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Armstrong 2005
Methods 2-arm RCT undertaken in the USA (in wound and academic centres)
Participants 162 adults
Inclusion criteria: presence of: wound from a diabetic foot amputation to the trans-
metatarsal level of the foot; adequate perfusion; University of Texas grade 2 or 3
Exclusion criteria: people presentingwith: activeCharcot arthropathy of the foot, wounds
resulting from burns, venous insufficiency, untreated cellulitis or osteomyelitis (after
amputation), collagen vascular disease, malignant disease in the wound; or people treated
with: corticosteroids, immunosuppressive drugs or chemotherapy, NPWT (in the last
30 days), growth factors, normothermic therapy; hyperbaric medicine, bioengineered
tissue products (in the last 30 days)
Key baselines covariates:
Wound area (cm²):
Group A: 22.3 (SD 23.4)
Group B: 19.2 (SD 17.6)
Wound duration (months):
Group A: 1.2 (SD 3.9)
Group B: 1.8 (SD 5.9)
75.3% of the study population had wounds that were < 30 days’ duration (classed as
acute wounds by the author) and 24.7% had wounds that were > 30 days’ duration
(classed as chronic wounds by authors)
Interventions Group A (n = 77): NPWT (V.A.C. system). No information provided regarding the
pressure applied or the cycle (e.g. constant/cyclical etc); dressing changes every 48 h.
Treatment conducted until wound closure or completion of 112 day assessment
Group B (n = 85): moist wound therapy with alginates, hydrocolloid, foam or hydrogel
dressings - adhering to standardised guidelines at the discretion of attending clinician.
Dressings changed every other day unless recommended by treating clinician
All participants received: off-loading therapy, preventatively and therapeutically as indi-
cated - a pressure relief sandal or walker was provided for all participants; sharp debride-
ment within 2 days of randomisation and as deemed necessary by treating clinician; and
measurement of prealbumin, albumin and glycosylated haemoglobin levels in 7 days
before entering the study. Low pre study albumin levels resulted in consultation with
nutritionist, and dietary supplement initiated if needed
Outcomes Primary review outcomes: number of wounds completely healed (defined as 100% re-ep-
ithelialisation without drainage and INCLUDED closure via surgery where the decision
for surgical closure was made by treating clinician); time to wound healing; amputation
Secondary review outcomes: other adverse events (serious and non-serious); resource use
Notes Follow-up: 112 days (16 weeks)
Outcome assessment: based on data from wound assessments and digital photographs
taken by treatment clinicians at days 0, 7, 14, 28, 42, 56, 84 and 112
A secondary analysis of trial data reported that 75% of wounds were ≤ 1 month in
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Armstrong 2005 (Continued)
duration (classed by authors as acute) and 25% were > 1 month in duration (classed by
authors as chronic).We noted thatmean baseline values for ulcer duration were obviously
very skewed
Funding: study funded by KCI - manufacturers of the V.A.C. intervention
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomisation was accomplished
by using www.randomizer.org to generate
15 blocks of 10 random numbers each.”
Comment: adequate methodology
Allocation concealment (selection bias) Low risk Quote: “numbers were systematically as-
signed to each treatment group, and sealed
envelopes containing opaque, black paper
labelled with assigned treatment and pa-
tient ID number were sequentially num-
bered and provided to each site. The black
paper was added to ensure that the contents
of the envelopes were not visible prior to
opening.”
Comment: adequate methodology
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “the decision for surgical closure of
amputation wounds was decided individu-
ally by the physician investigator.”
Comment: it is understandably not pos-
sible to blind participants or investigators
to whether or not they received NPWT.
However, given this, it is important that
any decision-making that might be af-
fected by performance bias is recognised
and blinding is introduced where possible.
We noted that unblinded health profes-
sionals were able to make decisions about
closure surgery that could then have re-
sulted in more wounds being closed (and
classed as healed) or amputated in 1 group
compared with the other. As a result of this,
we classed the risk of bias for this domain
as unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “neither patients nor investigators
were masked to the randomised treat-
ment assignment… However, notes that
the masking component of the study dealt
specifically with planimetry measurements
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Armstrong 2005 (Continued)
from digital photographs … concordance
between the investigator and the digital
planimetry provided independent confir-
mation of the primary efficacy endpoint of
complete wound healing.”
Comment: assessment of healing seems to
have had a blinded component
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no evidence of incomplete out-
come data
Other bias Unclear risk Potential funding bias; no evidence of other
bias
Blume 2008
Methods 2-arm RCT undertaken in the USA
Participants 342 adults; 341 randomised; ITT 335
Inclusion criteria: stage 2 or 3 (Wagner’s scale) calcaneal, dorsal or planter foot ulcer;
ulcer ≥ 2 cm² in area after debridement; adequate blood perfusion (various tests and
cut-offs reported)
Exclusion criteria: recognised active Charcot disease; ulcers resulting from electrical,
chemical or radiation burns; collagen vascular disease; ulcer malignancy; untreated os-
teomyelitis or cellulitis; uncontrolled hyperglycaemia; inadequate lower extremity per-
fusion; pregnant or nursing mothers; or ulcer treatment within 30 days of trial start with
normothermic or hyperbaric oxygen therapy, corticosteroids, immunosuppressive drugs,
chemotherapy, recombinant or autologous growth factor products, skin and dermal sub-
stitutes; or use of any enzymic debridement treatment
Key baselines covariates:
Wound area (cm²):
Group A: 13.5 (SD 18.2)
Group B: 11.0 (SD 12.7)
Wound duration (months)
Group A: 6.6 (SD 10.8)
Group B: 6.9 (SD 12.2)
Interventions Group A (n = 172): NPWT (V.A.C. system) applied according to manufacturer’s in-
structions, but no information provided about the pressure applied or the cycle (e.g.
constant/cyclical, etc.). Treatment continued until wound closure, or until there was
sufficient granulation tissue formation for healing by primary and secondary intention
Group B (n = 169): advanced moist wound therapy dressings used according to guide-
lines/local protocols - noted as being predominantly hydrogels and alginates
All participants received: assessment and debridement of ulcers within 2 days of ran-
domisation; off-loading therapy as deemed necessary
Outcomes Primary review outcomes: number of wounds completely healed (defined as 100% re-
epithelialisation without drainage or dressing requirement and INCLUDED closure via
surgery where the decision for surgical closure was made by treating clinician); time to
37Negative pressure wound therapy for treating foot wounds in people with diabetes mellitus (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Blume 2008 (Continued)
wound healing; amputation
Secondary review outcomes: other adverse events (serious and non-serious)
Notes Follow-up: 112 days (16 weeks)
Outcome assessment: participants examined weekly for the first 4 weeks and then every
other day until day 112, or ulcer closure by any means. Participants achieving closure
were followed up at 3 and 9 months
Funding: study funded by KCI - manufacturers of the V.A.C. intervention
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomization was accomplished by
generating blocks of numbers through http://
www.randomizer.org.”
Comment: adequate methodology
Allocation concealment (selection bias) Low risk Quote: “numbers were assigned to a treatment
group and sealed in opaque envelopes containing
black paper labelled with treatment and patient
ID. Envelopes were sequentially numbered be-
fore clinical trial site distribution. At patient ran-
domisation, treatment was assigned on the basis
of the next sequentially labelled envelope.”
Comment: adequate methodology
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: it is understandably not possible to
blind participants and investigators to whether
or not they receive NPWT. However, given this,
it is important that any decision-making that
might be affected by performance bias is recog-
nised and blinding is introduced where possible.
We note that unblinded health professionals were
able to make decisions about undertaking clo-
sure surgery that could then have resulted more
wounds being closed (and classed as healed) or
amputated in 1 group compared with the other.
As a result of this, we classed the risk of bias for
this domain as unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “blinded photographic evaluation was
conducted.”
Comment: while the main report has no discus-
sion of blinded outcome assessment, it is men-
tioned in the conference abstract describing the
study. However as with Armstrong 2005, we
noted that unblinded health professionals in 1
group were able to make decisions about under-
38Negative pressure wound therapy for treating foot wounds in people with diabetes mellitus (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Blume 2008 (Continued)
taking closure surgery that could then have re-
sulted more wounds being closed (and classed
as healed) or amputated. As a result of this, we
classed the risk of bias for this domain as unclear
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: 3 participants were excluded from
analysis in each arm as they did not receive the
trial treatment allocated. There were relatively
low numbers of exclusions, although ideally data
on these participants would have been included
in the RCT report. Additionally, 31% of partici-
pants in the NPWT group and 25% in the dress-
ing group were classed as being ’discontinued’ for
reasons that included adverse events, ineffective
treatment and death. It is not clear whether par-
ticipantswhowere discontinued for reasons other
than death were also censored from the analysis,
rather than being followed up. If discontinuation
did result in censoring in this open trial it may
have introduced bias
Other bias Unclear risk Potential funding bias; no evidence of other bias
Dalla-Paola 2010
Methods 2-arm RCT undertaken in Italy
Participants 130 adults.
Inclusion criteria: people presenting with infected open amputations or surgical dehis-
cence of minor amputations of level II-III A-B according to the University of Texas
Diabetic Wound Classification
Exclusion criteria: people with bleeding wounds or untreated osteomyelitis. In those
cases of recent debridement of the wound a minimum 24-h period was awaited before
applying a V.A.C. dressing
Key baselines covariates:
Wound area (cm²): not reported
Wound level University of Texas:
Group A: II: n = 20; III: n = 45
Group B: II: n = 22; III: n = 43
Interventions Group A (n = 65): V.A.C. therapy (V2) following surgical debridement
Group B (n = 65): advanced dressings (control group, C2) following surgical debride-
ment (dressings were changed 3 times per week and during every dressing change the
wound bed was inspected. Control group received advanced dressings such as alginate,
hydrofibre, silver-dressing or polyurethanes. The choice of dressing mostly depended on
the amount of exudate and presence of infection.)
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Dalla-Paola 2010 (Continued)
Outcomes Primary review outcomes: number of wounds completely healed (further); amputation
(after follow-up period)
Secondary review outcomes: number of wounds closed or covered with surgery; time to
closure or coverage surgery
Notes Follow-up period: end of therapy defined as complete coverage of the wound with
epithelial tissue
Funding: not reported
Only Study II included in this review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomization was performed using a com-
puterized randomization procedure.”
Comment: adequate methodology
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: it is understandably not possible to blind
participants and investigators to whether or not they
receive NPWT. However, given this, it is important
that any decision-making that might be affected by
performance bias is recognised and blinding is in-
troduced where possible. We noted that unblinded
health professionalswere able tomake decisions about
undertaking closure surgery that could then have re-
sulted in more wounds being closed (and classed as
healed) or amputated in 1 group compared with the
other. As a result of this, we classed the risk of bias
for this domain as unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “clinicians (non-blinded, participating in the
study) evaluated the wound bed and made a subjec-
tive estimation of the depth of the wound and of
the quality of the wound bed.” “A photographic doc-
umentation was carried out upon enrolment in the
study, during the intermediate phase and at the end of
the therapy. A planimetry of superficial wounds was
done to evaluate the dimensions of ulceratedwounds.
” “Presence andquantity of granulation tissuewas also
documented and microbiological examinations (after
wound debridement, based on wound biopsies) were
repeated. All patients with clinical signs of infection,
after microbiological examination, were treated with
targeted antibiotic therapy.”
Comment: as a result of this, we classed the risk of
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bias for this domain as unclear
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no evidence of incomplete outcome data
Other bias Low risk No evidence of other risk of bias
Karatepe 2011
Methods 2-arm RCT undertaken in Turkey
Participants 67 adults
Inclusion criteria: diabetic foot ulcers
Exclusion criteria: not reported
Key baselines covariates:
Wound area (cm²):
Group A: 35.7 (SD 6.4)
Group B: 29.7 (SD 5.2)
Wound duration (weeks):
Group A: 11.3 (SD 9.2)
Group B: 8.8 (SD 7.2)
Interventions Group A (n = 30): NPWT (V.A.C. system)
Group B (n = 37): conventional wound care treatment (described as daily wound care,
debridement and treatment of gangrenous tissue where required and use of sterilised
gauze dressing)
Clinical measures included standard diabetic treatment, daily wound care including
antiseptic bath, debridement, toe removal for gangrene when necessary and wound care
with conventional methods or V.A.C
Outcomes Primary review outcomes: time to healing
Secondary review outcomes: health-related quality of life measured with SF-36 (not
clearly reported)
Notes Follow-up: final SF-36 form completed 1 month after wound healing (mean in 4th
month of study)
Outcome assessment: healing time calculated as the time from hospital admission to re-
epithelisation. Table 2 titled as “Duration of granulation” but the table content presented
“time to healing.”
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomisation of the patients was ar-
ranged by the free use web based system (http://
www.tufts.edu\~gdall/PLAN.HTM).”
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Comment: classed as an adequate method
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not possible to blind participants and investigators
to whether or not they receive NPWT
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported
Other bias Low risk No evidence of other risk of bias
Lavery 2014
Methods 2-arm RCT undertaken in the USA
Participants 40 participants
Inclusion criteria: people with DM aged 21-90 years, surgical lower extremity wounds
(diabetic foot wounds after incision and drainage or amputation for infection), and
ankle-brachial indices > 0.70
Exclusion criteria: not reported
Key baselines covariates:
Wound area (cm²):
Group A: 20.1 (SD 14.3)
Group B: 34.6 (SD 32.9)
Wound volume (cm³):
Group A: 35.1 (SD 33.0)
Group B: 65.3 (SD 69.9)
History of amputation:
Group A: 65%
Group B: 65%
Wound duration: not reported
Interventions Group A (n = 20): 75 mmHg continuous pressure with a silicone-coated dressing (En-
genex with Bio-Dome Technology; ConvaTec, Skillman, NJ)
Group B (n = 20): 125 mmHg continuous pressure with a polyurethane foam dressing
(V.A.C. with GranuFoam dressing; Kinetic Concepts, Inc., San Antonio, TX)
Outcomes Primary review outcomes: no review relevant outcome reported
Secondary review outcomes: number of wounds closed or covered with surgery; adverse
events (we used data from Table 1 in the paper - 3 vs 2; however, discrepancy between
table and text which suggests 3 vs 1)
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Notes Follow-up: 4 weeks
Both NPWT devices were changed 3 times per week.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomised from a computer-generated
list”
Comment: classed as an adequate method
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: it is understandably not possible to
blind participants and investigators to whether or
not they receiveNPWT.However, given this, it is
important that any decision-making that might
be affected by performance bias is recognised
and blinding is introduced where possible. We
noted that unblinded health professionals were
able to make decisions about undertaking closure
surgery that could then have resulted in more
wounds being closed (and classed as healed) or
amputated in 1 group compared with the other.
As a result of this, we classed the risk of bias for
this domain as unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no evidence of incomplete outcome
data
Other bias Low risk No evidence of other risk of bias
Mody 2008
Methods 2-arm RCT undertaken in India
Participants 48 participants (recruited from inpatient wards), 15 of whom were reported to have DM
and a foot ulcer. Data for these 15 participants only were presented
Inclusion criteria: people admitted to general surgery, physical medicine and rehabil-
itation wards and referred by the surgical consultants for care of an acute or chronic
extremity, sacral or abdominal wound that could not be treated with primary closure
Exclusion criteria: ischaemic wounds; or wounds: in anatomical locations where an
adequate seal around the wound site could not be obtained; with exposed bowel or blood
vessels; with necrotic tissue that could not be debrided; with communicating fistulae;
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withmalignancy; with recent grafts; or presence of osteomyelitis; or receiving therapeutic
anticoagulation
Key baselines covariates (foot ulcers in people with DM only):
Wound area (cm²):
Group A: 25.7 (SD 9.7)
Group B: 48.1 (SD 53.5)
Wound duration (days):
Group A: 8.5 (SD 8.3)
Group B: 5.2 (SD 2.3)
Interventions Group A (n = 6): locally constructed (homemade) device: a sterilised, porous packing
material obtained from a local source was cut to fit the wound. A 14-French suction
catheter was tunnelled into the packing material, which then was placed into the wound
cavity. A sterile adhesive plastic drape (Dermincise, Vygon, UK) was cut to overlap the
surrounding skin and applied over the packing material, forming an airtight seal. Tubing
was used to attach the free end of the suction catheter to a wall suction canister. The
TNP timer was placed in circuit between the wall suction apparatus and the wall suction
canister
The TNP timer, constructed from local electronics, was designed to cycle wall suction
intermittently using a simple timed switch and a system of valves. For the study protocol,
the timer was set to cycle for 2 minutes on, followed by 5 minutes off. Wall suction
pressure was set at 125 mmHg. In sensitive wounds, suction was reduced to a tolerable
level (usually 50-100 mmHg) until it could be comfortably increased. For oedematous
wounds, the suctionwas kept on a continuous setting until oedema had been reduced and
an intermittent regimen could be followed. The dressing was changed every 2 days unless
otherwise scheduled by the treating physician. Wounds were debrided as required to
keep the wound bed free of necrotic tissue. Participants receiving NPWT who no longer
required hospitalisations for their primary diagnosis, or could not afford to remain in
the hospital, remained in the study with conventional wound dressings in the outpatient
setting, but outcomes were analysed in the original treatment groups
Group B (n = 9): saline-soaked gauze and dry pads used to cover the wound. Dressing
changes typically performed twice daily; frequency adjusted according to the judgement
of the treating physician
Wounds in both treatment groups were debrided before dressing application
Outcomes Primary review outcomes: number of wounds completely healed (satisfactory healing
defined as completewound closure by secondary intentionorwound readiness for delayed
primary closure as determined by the study investigator and treating surgeon)
Secondary review outcomes: number of wounds closed or covered with surgery
Notes Participants were followed until wound closure or being lost to follow-up for a mean of
26.3 days (SD 18.5) in the control and 33.1 days (SD 37.3) in the treatment group
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Quote: “wounds that met inclusion and exclusion
criteria were assessed for size (in a manner that al-
lowed blinding) and then block-randomized using a
concealed computer-generated table in a 1-to-2 ratio
of TNP closure versus conventional wound dressing.
”
Comment: adequate method
Allocation concealment (selection bias) Unclear risk Quote: “following enrolment, wound size was as-
sessed using computer-aided measurements of digi-
tal photographs and block-randomized to the study
arms using a concealed allocation table.”
Comment: unclear how allocation concealment was
conducted
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Seems that participants were analysed in groups as
randomised
Other bias Low risk No evidence of other risk of bias
Nain 2011
Methods 2-arm RCT undertaken in India
Participants 30 participants
Inclusion criteria: age group 20-75 years, ulcer area 50-200 cm², diagnosis of DMmade
by American Diabetes Association Criteria
Exclusion criteria: aged < 20 years or > 75 years; obvious septicaemia; osteomyelitis;
wounds resulting from venous insufficiency; malignant disease in a wound; people be-
ing treated with corticosteroids, immunosuppressive drugs or chemotherapy; any other
serious pre-existing cardiovascular, pulmonary and immunological disease
Key baselines covariates: not reported
Interventions Group A: negative-pressure dressing therapy. Foam-based dressing covered with adhesive
drape. An evacuation tube embedded in the foam was connected to a fluid collection
canister contained within a portable vacuum/suction machine. Subatmospheric (nega-
tive) pressure was applied within a range of -50 mmHg to -125 mmHg intermittently
3 times a day. NPWT dressings were changed when required. Subsequently, the control
group received twice daily saline-moistened gauze dressings
Group B: twice daily dressing changes with saline-moistened gauze
Cointerventions: wounds underwent initial sharp debridement to remove necrotic tissue
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and slough as far as possible. Standard antibiotic regimens were administered to all
participants which consisted of broad-spectrum antibiotics initially and later according
to the culture sensitivity report
Outcomes Primary review outcomes: number of wounds completely healed (complete healing de-
fined as 100% wound closure with re-epithelialisation or scab with no wound drainage
present and no dressing required; complete responders: complete healing of lower limb
ulcers)
Secondary review outcomes: no review relevant outcome reported
Notes Follow-up: 8 weeks
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “patients were randomly divided into two
groups - study group and control group.”
Comments: not reported how sequence for randomi-
sation was generated
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not possible to blind participants and investigators
to whether or not they receive NPWT
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “the patientswhounderwent belowknee am-
putation were excluded from this analysis.”
Comment: surely this is attrition bias. We do not
know how many people underwent amputation (it
was unclear what the 80% vs 60% refer to. In the
text it said that 9 wounds in the A group as 60% at
4 weeks)
Other bias Unclear risk Not reported
46Negative pressure wound therapy for treating foot wounds in people with diabetes mellitus (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Novinš ak 2010
Methods 3-arm RCT undertaken in Croatia
Participants 27 adult inpatients
Inclusion criteria: complicated diabetic ulcer (Wagner 2-5) managed to international
guidelines for treatment protocol (confirmed with the author that these were all foot
wounds)
Exclusion criteria: revascularisation, reconstruction and amputation procedures were not
considered in this study
Key baselines covariates: not reported
Wound duration (months): not reported
Interventions Group A (n = 7): NPWT
Group B (n = 12): moist dressings
Group C (n = 8): classic gauze
Surgical debridement, off-loading, comorbidity treatment and appropriate wound care
were performed
Outcomes Primary review outcome: healing rate (author defined as wound closure - personal con-
tact)
Secondary review outcomes: no review relevant outcome reported
Notes Follow-up: 2 months, extracted from abstract only
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported
Other bias Unclear risk Not reported
47Negative pressure wound therapy for treating foot wounds in people with diabetes mellitus (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Vaidhya 2015
Methods 2-arm RCT undertaken in India
Participants 60 participants
Inclusion criteria: people with ulcers on dorsum of foot of size > 10 cm². Adequate blood
circulation was assessed by doing lower limb arterial Doppler
Exclusion criteria: people with osteomyelitis, peripheral vascular disease or malignancy
Key baselines covariates: not reported
Interventions Group A: NPWTdressing (a usual suction machine generating pressure of−80 to−150
mmHg, Ryle’s tube, piece of foam cut according to size and shape of ulcer, and adhesive
transparent dressing (OpSite by Smith & Nephews, UK). The suction was applied 30
minutes on and 30 minutes off.)
Group B: conventional dressing (cleaning with povidine iodine solution with or without
hydrogen peroxide and applying moist gauze to wound and dressing closed by cotton
bandage)
All participants were given medical therapy for DM and antibiotics given according to
culture and sensitivity patterns. All foot ulcers were surgically debrided prior to initiation
of NPWT or conventional treatment. In the NPWT group, dressings were changed
every 48-72 h. In the control group, conventional dressings were applied at the time
of surgical debridement and changed twice a day thereafter. Participants with failure of
dressings were treated with other methods of dressing
Outcomes Primary review outcomes: amputation (data for alternative therapy or amputation)
Secondary review outcomes: number of wounds closed or covered with surgery
Notes Follow-up: end point of study was when wound was ready for either skin grafting or
secondary suturing
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “sixty patients were randomised into ei-
ther the experimental NPWTgroup or conventional
dressing group (control).”
Comment: method of sequence generation not re-
ported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: it is understandably not possible to blind
participants and investigators to whether or not they
receive NPWT. However, given this, it is impor-
tant that any decision-making that might be af-
fected by performance bias is recognised and blind-
ing is introduced where possible. We noted that un-
blinded health professionals were able to make deci-
sions about undertaking closure surgery that could
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then have resulted more wounds being closed (and
classed as healed) or amputated in 1 group compared
with the other. As a result of this, we classed the risk
of bias for this domain as unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no evidence of incomplete outcome data
Other bias Low risk No evidence of other risk of bias
Zhang 2017
Methods 2-arm RCT undertaken in China
Participants 40 participants
Inclusion criteria: clinical diagnosis of type 2 DM, wound was consistent with the diag-
nosis of a chronic wound, 2 ≤Wagner grade ≤ 4, continuous existence of the diabetic
foot lesion for a minimum of 1 month
Exclusion criteria: refusal to give written informed consent; aged < 18 years; pregnancy;
presence of expected non-compliance with the requirements of the study estimated by
investigator at time point of inclusion; necrotic tissue that could not be debrided; ma-
lignancy of the wound; severe heart disease, heart failure, unstable angina pectoris, my-
ocardial infarction or severe systemic infection; severe renal insufficiency, with a serum
creatinine level > 106 µmol/L; liver dysfunction, with alanine aminotransferase levels >
125 U/L or glutamic-oxalacetic transaminase level > 87.5 U/L; application of immuno-
suppressive agents and growth factors; poor compliance, death or unable to complete
the course of treatment (during treatment); contraindications for surgery or people did
not agree to having surgery
Key baselines covariates:
Wound area and wound duration not reported
Interventions Group A: vacuum sealing drainage group: wounds cleaned and disinfected by repeat-
edly washing with sterilised physiological saline, hydrogen peroxide and iodine solution
and then covered with negative-pressure material according to the shape and size after
debridement; dressing changed every 7 days. Negative pressure was maintained at -120
to -400 mmHg
Group B: routine dressing: 0.5% dilute iodoform gauze and Vaseline gauze dressing,
changed every other day
Outcomes Primary review outcomes: number of wounds completely healed (described as “cured”)
; amputation
Secondary review outcomes: no review relevant outcome reported
49Negative pressure wound therapy for treating foot wounds in people with diabetes mellitus (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Zhang 2017 (Continued)
Notes Infiltration of the wound surface, granulation tissue growth and epitheliumof the wound
surface were observed every 7 days for 1 month
Funding: Science and Technology Grant
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: it is understandably not possible to
blind participants and investigators to whether or
not they receive NPWT. However, given this, it
is important that any decision-making that might
be affected by performance bias is recognised and
blinding is introduced where possible. We noted
that unblinded health professionals were able to
make decisions about undertaking closure surgery
that could then have resulted in more wounds be-
ing closed (and classed as healed) or amputated in 1
group compared with the other. As a result of this,
we classed the risk of bias for this domain as unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no evidence of incomplete outcome
data
Other bias Low risk No evidence of other risk of bias
Zhu 2014
Methods 2-arm RCT undertaken in China
Participants 60 participants
Inclusion criteria: duration of DM 10-20 years; mean fasting blood glucose at admission
≥ 10 mmol/L; diabetic foot by Wagner grading method of ≥ 2; diabetic foot ulcers
distributed in the distal end of the toe, toe plantar joints, heel, ankle and 1/3 lower leg
Exclusion criteria: DM not diagnosed; cancerous ulcer or ulcer malignant, osteomyelitis;
taking certain uncommon drugs, chemotherapy, dialysis; difficult to control high blood
sugar (glycosylated haemoglobin > 12%)
Key baselines covariates:
Wound area (cm²):
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Group A: 39.9 (SD 19.8)
Group B: 40.4 (SD 20.4)
Wound duration (days)
Group A: 51.4 (SD 36.3)
Group B: 52.6 (SD 27.6)
Interventions Group A: vacuum sealing drainage group, conventional treatment combined with the
vacuum sealing drainage technology
Group B: traditional treatment group, regulating blood sugar level, dressing and tradi-
tional debridement
Cointerventions: all participants received blood sugar control and debridement
Outcomes Primary review outcomes: number of wounds completely healed (defined as cured
wound: no amputation is needed); amputation
Secondary review outcomes: number of wounds closed or covered with surgery; wound
recurrence
Notes Follow-up: not specified for wound healing; ulcer recurrence was observed in 6-10
months
Outcome assessment: healing time calculated only for cured wounds (no amputation
needed); preparation time described as time for skin/flap grafting
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: it is understandably not possible to
blind participants and investigators to whether or
not they receive NPWT. However, given this, it
is important that any decision-making that might
be affected by performance bias is recognised and
blinding is introduced where possible. We noted
that unblinded health professionals were able to
make decisions about undertaking closure surgery
that could then have resulted more wounds being
closed (and classed as healed) or amputated in 1
group compared with the other. As a result of this,
we classed the risk of bias for this domain as unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no evidence of incomplete outcome
data
Other bias Low risk No evidence of other risk of bias
DM: diabetes mellitus; h: hour; ITT: intention-to-treat population; n: number of participants; NPWT: negative pressure wound
therapy; RCT: randomised controlled trial; SD: standard deviation; SF-36: 36-item Short Form; TNP: topical negative pressure
(synonym for NPWT).
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Armstrong 2012 Included multiple wounds types. Unable to obtain diabetic foot wound data separately
Braakenburg 2005 Included multiple wounds types. Unable to obtain diabetic foot wound data separately
Chong 2011 Randomised crossover trial; no relevant outcome reported
Eginton 2003 Due to focus on biochemical and related outcomes and the very short follow-up, we considered that
relevant outcomes were not measured (they were not reported)
Etoz 2007 Not an RCT, as participants allocated using alternation
Foo 2004 Due to focus on biochemical and related outcomes and the very short follow-up, we considered that
relevant outcomes were not measured (they were not reported)
Formosa 2015 Not an RCT
Gonzalez 2017 Included multiple wound types. Unable to obtain diabetic foot wound data separately
Lone 2014 Not an RCT, as participants allocated using odd and even numbers (quasi-randomised study)
Maggio 2010 Treatment with NPWT was not the only systematic difference between groups (intervention group
receiving NPWT also received autologous fibroblasts and skin grafting)
McCallon 2000 Not an RCT, as participants allocated using alternation. Coin flipped for first participant and then
participants allocated by alternation
Moghazy 2015 Not an RCT, as “stratified sequential allocation method” used
Mouës 2004 Not a diabetic foot wound study population
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Perez 2010 Included multiple wound types. Unable to obtain diabetic foot wound data separately
Rahmanian-Schwarz 2012 Included multiple wound types. Unable to obtain diabetic foot wound data separately
Ravari 2013 The investigators described a non-random component in the sequence generation process
Riaz 2010 Included wounds in people with diabetes in regions other than the foot (legs and back). Unable to
obtain diabetic foot wound data separately
Sajid 2015 Due to focus on biochemical and related outcomes and the very short follow-up, we considered that
relevant outcomes were not measured (they were not reported)
Sepulveda 2009 Due to focus on biochemical and related outcomes and the very short follow-up, we considered that
relevant outcomes were not measured (they were not reported)
Sun 2007 Crossover design and no relevant outcome reported
Sun 2015 NPWT was not the only difference between trial arms.
Tuncel 2013 Included multiple wounds types. Unable to obtain diabetic foot wound data separately
Ugurlar 2017 The investigators described a non-random component in the sequence generation process
Wang 2016 Due to focus on biochemical and related outcomes and the very short follow-up, we considered that
relevant outcomes were not measured (they were not reported)
Yang 2014 Due to focus on biochemical and related outcomes and the very short follow-up, we considered that
relevant outcomes were not measured (they were not reported)
Yang 2017a Due to focus on biochemical and related outcomes and the very short follow-up, we considered that
relevant outcomes were not measured (they were not reported)
Yang 2017b Due to focus on biochemical and related outcomes and the very short follow-up, we considered that
relevant outcomes were not measured (they were not reported)
Zhang 2014 Due to focus on biochemical and related outcomes and the very short follow-up, we considered that
relevant outcomes were not measured (they were not reported)
NPWT: negative pressure wound therapy; RCT: randomised controlled trial.
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Characteristics of ongoing studies [ordered by study ID]
ACTRN12612000885897
Trial name or title A pilot randomised controlled trial of negative pressure wound therapy (NPWT) in hospital in the home
(HITH) to treat post-operative foot wounds
Methods RCT
Participants Men and women aged > 18 years; postoperative foot amputation to the transmetatarsal level of foot ≥ 5 cm²
to ≤ 20 cm² measured by digital planimetry
Interventions NPWT vs standard care
Outcomes Proportion of wounds healed; time to healing; frequency of treatment; wound recurrence; resources used/
costs; recruitment rates; pain and health-related quality of life
Starting date 17 August 2012
Contact information carolina.weller@monash.edu
Notes Not yet recruiting
ChiCTR-TRC-12002700
Trial name or title A prospective multicenter assessment of Foryou NPWT security and effectiveness in promoting the healing
of diabetic foot ulcer
Methods RCT
Participants People with type 1 or type 2 DM and with DFUs, including amputation wounds, were considered suitable
for NPWT by the author of this study
Interventions NPWT vs advanced wound dressing treatment
Outcomes Change in wound area; complete healing rate
Starting date 1 August 2012
Contact information yaomingxue@126.com
Notes Recruitment status not updated
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DRKS00000059
Trial name or title Treatment of diabetic foot wounds by vacuum-assisted closure
Methods RCT
Participants Men and women aged > 18 years with diabetic foot wounds
Interventions NPWT vs standard conventional moist wound therapy
Outcomes Time until complete (100%) wound closure
Starting date 1 August 2009
Contact information PrivateUniversitätWitten/HerdeckeGmbHInstitut für Forschung inderOperativenMedizin,Ostmerheimer
Str. 200, 51109 Cologne, Germany
Notes Recruiting suspended before start date
ISRCTN64926597
Trial name or title Comparing treatments for diabetic foot ulcers
Methods RCT
Participants Adults aged ≥ 18 years with DM and a foot ulcer
Interventions Group 1: TAU
Group 2: TAU + HD
Group 3: TAU + HD + NPWT
Group 4: TAU + HD + DCD
Group 5: TAU + HD + DCD + NPWT
Outcomes Reduction in index ulcer area size; time to healing
Starting date April 2017
Contact information r.m.gilberts@leeds.ac.uk
Notes Recruitment status: recruiting
Overall trial end date: 31 March 2022
DCD: decellularised dermal allograft; DM: diabetes mellitus; DFU: diabetic foot ulcer; HD: hydrosurgical debridement; NPWT:
negative pressure wound therapy; RCT: randomised controlled trial; TAU: treatment as usual.
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D A T A A N D A N A L Y S E S
Comparison 1. Negative pressure wound therapy (NPWT) compared with dressings in postoperative wounds
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion of wounds healed 1 162 Risk Ratio (M-H, Fixed, 95% CI) 1.44 [1.03, 2.01]
2 Time to healing 1 162 Hazard Ratio (Fixed, 95% CI) 1.91 [1.21, 2.99]
3 Amputations 2 292 Risk Ratio (M-H, Fixed, 95% CI) 0.38 [0.14, 1.02]
4 Number of wounds closed or
covered with surgery
1 130 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.95, 1.09]
5 Adverse events 1 162 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.72, 1.28]
Comparison 2. NPWT compared with dressings in diabetic foot ulcers
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion of wounds healed 5 486 Risk Ratio (IV, Fixed, 95% CI) 1.40 [1.14, 1.72]
1.1 Advanced dressings 1 341 Risk Ratio (IV, Fixed, 95% CI) 1.49 [1.11, 2.01]
1.2 Basic contact dressings 2 45 Risk Ratio (IV, Fixed, 95% CI) 1.34 [0.83, 2.16]
1.3 Anti-microbial dressings 2 100 Risk Ratio (IV, Fixed, 95% CI) 1.32 [0.93, 1.87]
2 Amputations 3 441 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.15, 0.70]
3 Number of wounds closed or
covered with surgery
3 129 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.85, 1.24]
4 Wound recurrence 1 60 Risk Ratio (M-H, Fixed, 95% CI) 0.5 [0.10, 2.53]
Comparison 3. Low compared with high pressure of NPWT in diabetic foot ulcers
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of wounds closed or
covered with surgery
1 40 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.47, 1.47]
2 Adverse events 1 40 Risk Ratio (M-H, Fixed, 95% CI) 1.5 [0.28, 8.04]
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Analysis 1.1. Comparison 1 Negative pressure wound therapy (NPWT) compared with dressings in
postoperative wounds, Outcome 1 Proportion of wounds healed.
Review: Negative pressure wound therapy for treating foot wounds in people with diabetes mellitus
Comparison: 1 Negative pressure wound therapy (NPWT) compared with dressings in postoperative wounds
Outcome: 1 Proportion of wounds healed
Study or subgroup NPWT Dressings Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Armstrong 2005 43/77 33/85 100.0 % 1.44 [ 1.03, 2.01 ]
Total (95% CI) 77 85 100.0 % 1.44 [ 1.03, 2.01 ]
Total events: 43 (NPWT), 33 (Dressings)
Heterogeneity: not applicable
Test for overall effect: Z = 2.14 (P = 0.032)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours dressings Favours NPWT
Analysis 1.2. Comparison 1 Negative pressure wound therapy (NPWT) compared with dressings in
postoperative wounds, Outcome 2 Time to healing.
Review: Negative pressure wound therapy for treating foot wounds in people with diabetes mellitus
Comparison: 1 Negative pressure wound therapy (NPWT) compared with dressings in postoperative wounds
Outcome: 2 Time to healing
Study or subgroup NPWT Dressings log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Armstrong 2005 77 85 0.645 (0.23) 100.0 % 1.91 [ 1.21, 2.99 ]
Total (95% CI) 77 85 100.0 % 1.91 [ 1.21, 2.99 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.80 (P = 0.0050)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours dressings Favours NPWT
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Analysis 1.3. Comparison 1 Negative pressure wound therapy (NPWT) compared with dressings in
postoperative wounds, Outcome 3 Amputations.
Review: Negative pressure wound therapy for treating foot wounds in people with diabetes mellitus
Comparison: 1 Negative pressure wound therapy (NPWT) compared with dressings in postoperative wounds
Outcome: 3 Amputations
Study or subgroup NPWT Dressings Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Armstrong 2005 2/77 9/85 63.1 % 0.25 [ 0.05, 1.10 ]
Dalla-Paola 2010 3/65 5/65 36.9 % 0.60 [ 0.15, 2.41 ]
Total (95% CI) 142 150 100.0 % 0.38 [ 0.14, 1.02 ]
Total events: 5 (NPWT), 14 (Dressings)
Heterogeneity: Chi2 = 0.75, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 1.91 (P = 0.056)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours NPWT Favours dressing
Analysis 1.4. Comparison 1 Negative pressure wound therapy (NPWT) compared with dressings in
postoperative wounds, Outcome 4 Number of wounds closed or covered with surgery.
Review: Negative pressure wound therapy for treating foot wounds in people with diabetes mellitus
Comparison: 1 Negative pressure wound therapy (NPWT) compared with dressings in postoperative wounds
Outcome: 4 Number of wounds closed or covered with surgery
Study or subgroup NPWT Dressing Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dalla-Paola 2010 63/65 62/65 100.0 % 1.02 [ 0.95, 1.09 ]
Total (95% CI) 65 65 100.0 % 1.02 [ 0.95, 1.09 ]
Total events: 63 (NPWT), 62 (Dressing)
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.65)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours NPWT Favours dressing
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Analysis 1.5. Comparison 1 Negative pressure wound therapy (NPWT) compared with dressings in
postoperative wounds, Outcome 5 Adverse events.
Review: Negative pressure wound therapy for treating foot wounds in people with diabetes mellitus
Comparison: 1 Negative pressure wound therapy (NPWT) compared with dressings in postoperative wounds
Outcome: 5 Adverse events
Study or subgroup NPWT Dressings Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Armstrong 2005 40/77 46/85 100.0 % 0.96 [ 0.72, 1.28 ]
Total (95% CI) 77 85 100.0 % 0.96 [ 0.72, 1.28 ]
Total events: 40 (NPWT), 46 (Dressings)
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours NPWT Favours dressings
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Analysis 2.1. Comparison 2 NPWT compared with dressings in diabetic foot ulcers, Outcome 1 Proportion
of wounds healed.
Review: Negative pressure wound therapy for treating foot wounds in people with diabetes mellitus
Comparison: 2 NPWT compared with dressings in diabetic foot ulcers
Outcome: 1 Proportion of wounds healed
Study or subgroup NPWT Dressings Risk Ratio Weight Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
1 Advanced dressings
Blume 2008 73/172 48/169 47.5 % 1.49 [ 1.11, 2.01 ]
Subtotal (95% CI) 172 169 47.5 % 1.49 [ 1.11, 2.01 ]
Total events: 73 (NPWT), 48 (Dressings)
Heterogeneity: not applicable
Test for overall effect: Z = 2.66 (P = 0.0078)
2 Basic contact dressings
Mody 2008 1/6 1/9 0.6 % 1.50 [ 0.11, 19.64 ]
Nain 2011 12/15 9/15 17.7 % 1.33 [ 0.82, 2.16 ]
Subtotal (95% CI) 21 24 18.3 % 1.34 [ 0.83, 2.16 ]
Total events: 13 (NPWT), 10 (Dressings)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 1.20 (P = 0.23)
3 Anti-microbial dressings
Zhang 2017 17/20 13/20 30.3 % 1.31 [ 0.90, 1.89 ]
Zhu 2014 7/30 5/30 3.9 % 1.40 [ 0.50, 3.92 ]
Subtotal (95% CI) 50 50 34.2 % 1.32 [ 0.93, 1.87 ]
Total events: 24 (NPWT), 18 (Dressings)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.55 (P = 0.12)
Total (95% CI) 243 243 100.0 % 1.40 [ 1.14, 1.72 ]
Total events: 110 (NPWT), 76 (Dressings)
Heterogeneity: Chi2 = 0.36, df = 4 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 3.25 (P = 0.0011)
Test for subgroup differences: Chi2 = 0.34, df = 2 (P = 0.85), I2 =0.0%
0.01 0.1 1 10 100
Favours dressings Favours NPWT
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Analysis 2.2. Comparison 2 NPWT compared with dressings in diabetic foot ulcers, Outcome 2
Amputations.
Review: Negative pressure wound therapy for treating foot wounds in people with diabetes mellitus
Comparison: 2 NPWT compared with dressings in diabetic foot ulcers
Outcome: 2 Amputations
Study or subgroup NPWT Dressings Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Blume 2008 7/172 17/169 66.9 % 0.40 [ 0.17, 0.95 ]
Zhang 2017 1/20 2/20 7.8 % 0.50 [ 0.05, 5.08 ]
Zhu 2014 0/30 6/30 25.3 % 0.08 [ 0.00, 1.31 ]
Total (95% CI) 222 219 100.0 % 0.33 [ 0.15, 0.70 ]
Total events: 8 (NPWT), 25 (Dressings)
Heterogeneity: Chi2 = 1.36, df = 2 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 2.88 (P = 0.0039)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours NPWT Favours dressing
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Analysis 2.3. Comparison 2 NPWT compared with dressings in diabetic foot ulcers, Outcome 3 Number of
wounds closed or covered with surgery.
Review: Negative pressure wound therapy for treating foot wounds in people with diabetes mellitus
Comparison: 2 NPWT compared with dressings in diabetic foot ulcers
Outcome: 3 Number of wounds closed or covered with surgery
Study or subgroup NPWT Dressings Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mody 2008 0/6 3/9 6.1 % 0.20 [ 0.01, 3.36 ]
Vaidhya 2015 27/30 23/30 48.9 % 1.17 [ 0.93, 1.48 ]
Zhu 2014 23/30 19/24 44.9 % 0.97 [ 0.73, 1.29 ]
Total (95% CI) 66 63 100.0 % 1.02 [ 0.85, 1.24 ]
Total events: 50 (NPWT), 45 (Dressings)
Heterogeneity: Chi2 = 2.79, df = 2 (P = 0.25); I2 =28%
Test for overall effect: Z = 0.23 (P = 0.82)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours dressing Favours NPWT
Analysis 2.4. Comparison 2 NPWT compared with dressings in diabetic foot ulcers, Outcome 4 Wound
recurrence.
Review: Negative pressure wound therapy for treating foot wounds in people with diabetes mellitus
Comparison: 2 NPWT compared with dressings in diabetic foot ulcers
Outcome: 4 Wound recurrence
Study or subgroup NPWT Dressings Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Zhu 2014 2/30 4/30 100.0 % 0.50 [ 0.10, 2.53 ]
Total (95% CI) 30 30 100.0 % 0.50 [ 0.10, 2.53 ]
Total events: 2 (NPWT), 4 (Dressings)
Heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours NPWT Favours dressings
62Negative pressure wound therapy for treating foot wounds in people with diabetes mellitus (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.1. Comparison 3 Low compared with high pressure of NPWT in diabetic foot ulcers, Outcome 1
Number of wounds closed or covered with surgery.
Review: Negative pressure wound therapy for treating foot wounds in people with diabetes mellitus
Comparison: 3 Low compared with high pressure of NPWT in diabetic foot ulcers
Outcome: 1 Number of wounds closed or covered with surgery
Study or subgroup
NPWT
with 75
mmHg
NPWT with
125 mmHg Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lavery 2014 10/20 12/20 100.0 % 0.83 [ 0.47, 1.47 ]
Total (95% CI) 20 20 100.0 % 0.83 [ 0.47, 1.47 ]
Total events: 10 (NPWT with 75 mmHg), 12 (NPWT with 125 mmHg)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours NPWT 125 mmHg Favours NPWT 75 mmHg
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Analysis 3.2. Comparison 3 Low compared with high pressure of NPWT in diabetic foot ulcers, Outcome 2
Adverse events.
Review: Negative pressure wound therapy for treating foot wounds in people with diabetes mellitus
Comparison: 3 Low compared with high pressure of NPWT in diabetic foot ulcers
Outcome: 2 Adverse events
Study or subgroup
NPWT
with 75
mmHg
NPWT with
125 mmHg Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lavery 2014 3/20 2/20 100.0 % 1.50 [ 0.28, 8.04 ]
Total (95% CI) 20 20 100.0 % 1.50 [ 0.28, 8.04 ]
Total events: 3 (NPWT with 75 mmHg), 2 (NPWT with 125 mmHg)
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours NPWT 125 mmHg Favours NPWT 75 mmHg
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Table 1. Study details (Continued)
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Table 1. Study details (Continued)
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Table 1. Study details (Continued)
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Table 1. Study details (Continued)
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Table 1. Study details (Continued)
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Table 1. Study details (Continued)
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Table 1. Study details (Continued)
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A: 27/
30
(90%)
Group
B: 23/
30 (67.
7%)
Not re-
ported
prop-
erly -
not all
ulcers
reached
this
point
Not re-
ported
Not re-
ported
Lim-
ited
data:
not ex-
tracted
Not re-
ported
Zhang
2017 Chronic
dia-
betic
ulcers
Group
A: vac-
uum
sealing
drainage
(n =
20)
Group
Not re-
ported
Inter-
ven-
tions
were
ad-
minis-
tered
in hos-
Not re-
ported
Group
A: 17/
20
(85%)
Group
B: 13/
20
(65%)
Group
A: 1/
20
(5%)
Group
B: 2/
20
(10%)
Not re-
ported
Not re-
ported
Not re-
ported
Not re-
ported
Not re-
ported
Not re-
ported
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Table 1. Study details (Continued)
B:
gauze
dress-
ing (n
= 20)
pital
Zhu
2014
Dia-
betic
foot
wounds
Group
A: vac-
uum
sealing
drainage
(n =
30)
Group
B: tra-
di-
tional
treat-
ment
(povi-
done/
lipid
dress-
ing) (n
= 30)
Not re-
ported
Fol-
low-
up to
6-10
months
for
wounds
recur-
rence
Vac-
uum
sealing
drainage
ad-
minis-
tered
when
neces-
sary at
several
time
points
Not re-
ported
prop-
erly -
not all
ulcers
healed
Group
A: 7/
30
(23%)
Group
B: 5/
30
(17%)
Group
A: 0
Group
B: 6/
30
(20%)
Of
healed
wounds
by sec-
ondary
surgery
(skin/
flap
graft-
ing):
Group
A: 23/
30
Group
B: 19/
24
Not re-
ported
prop-
erly -
not all
ulcers
reached
this
point
Not re-
ported
Not re-
ported
Not re-
ported
Group
A: 2
Group
B: 4
Fol-
low-up
time:
6-10
months
h: hour; IQR: interquartile range; ITT: intention to treat; n: number of participants; NPWT: negative pressure wound therapy; SF-
36: 36-item Short Form; TNP: topical negative pressure.
A P P E N D I C E S
Appendix 1. Search strategies
Cochrane Wounds Specialised Register
1 MESH DESCRIPTOR Foot Ulcer EXPLODE ALL AND INREGISTER
2 MESH DESCRIPTOR Diabetic Foot EXPLODE ALL AND INREGISTER
3 (diabet* near3 ulcer*) AND INREGISTER
4 (diabet* near3 (foot or feet)) AND INREGISTER
5 (diabet* near3 wound*) AND INREGISTER
6 (diabet* near3 defect*) AND INREGISTER
7 MESH DESCRIPTOR Amputation EXPLODE ALL AND INREGISTER
8 MESH DESCRIPTOR Amputation Stumps EXPLODE ALL AND INREGISTER
9 (diabetic near3 amputat*) AND INREGISTER
10 MESH DESCRIPTOR Debridement EXPLODE ALL AND INREGISTER
11 debrid* or slough* or deslough* AND INREGISTER
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12 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11
13 MESH DESCRIPTOR Negative-Pressure Wound Therapy EXPLODE ALL AND INREGISTER
14 MESH DESCRIPTOR Suction EXPLODE ALL AND INREGISTER
15 MESH DESCRIPTOR Vacuum EXPLODE ALL AND INREGISTER
16 MESH DESCRIPTOR Drainage EXPLODE ALL AND INREGISTER
17 (negative pressure or negative-pressure or TNP) AND INREGISTER
18 (sub-atmospheric or subatmospheric) AND INREGISTER
19 ((seal* next surface*) or (seal* next aspirat*)) AND INREGISTER
20 (wound near2 suction*) AND INREGISTER
21 ((foam next suction) or (suction next dressing*)) AND INREGISTER
22 (vacuum assisted or vacuum-assisted or VAC) AND INREGISTER
23 ((vacuum next therapy) or (vacuum next dressing*) or (vacuum next seal*) or (vacuum next closure) or (vacuum next compression)
or (vacuum next pack*) or (vacuum next drainage) or (suction* next drainage)) AND INREGISTER
24 #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23
25 #12 AND #24
The Cochrane Central Register of Controlled Clinical Trials (CENTRAL)
#1 MeSH descriptor: [Foot Ulcer] explode all trees
#2 MeSH descriptor: [Diabetic Foot] explode all trees
#3 (diabet* near/3 ulcer*):ti,ab,kw
#4 (diabet* near/5 (foot or feet)):ti,ab,kw
#5 (diabet* near/5 wound*):ti,ab,kw
#6 (diabet* near/3 defect*):ti,ab,kw
#7 MeSH descriptor: [Amputation] explode all trees
#8 MeSH descriptor: [Amputation Stumps] explode all trees
#9 (diabetic near/3 amputat*):ti,ab,kw
#10 MeSH descriptor: [Debridement] explode all trees
#11 (debrid* or slough* or deslough*):ti,ab,kw
#12 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11
#13 MeSH descriptor: [Negative-Pressure Wound Therapy] explode all trees
#14 MeSH descriptor: [Suction] explode all trees
#15 MeSH descriptor: [Vacuum] explode all trees
#16 MeSH descriptor: [Drainage] explode all trees
#17 (“negative pressure” or negative-pressure or TNP):ti,ab,kw
#18 (sub-atmospheric or subatmospheric):ti,ab,kw
#19 ((seal* next surface*) or (seal* next aspirat*)):ti,ab,kw
#20 (wound near/2 suction*):ti,ab,kw
#21 ((foam next suction) or (suction next dressing*)):ti,ab,kw
#22 (vacuum assisted or vacuum-assisted or VAC):ti,ab,kw
#23 ((vacuum next therapy) or (vacuum next dressing*) or (vacuum next seal*) or (vacuum near closure) or (vacuum next compression)
or (vacuum next pack*) or (vacuum next drainage) or (suction next drainage)):ti,ab,kw
#24 #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23
#25 #12 and #24
Ovid MEDLINE
1 exp Foot Ulcer/
2 exp Diabetic Foot/
3 (diabet* adj3 ulcer*).tw.
4 (diabet* adj3 (foot or feet)).tw.
5 (diabet* adj3 wound*).tw.
6 (diabet* adj3 defect*).tw.
7 exp Amputation/
8 exp Amputation Stumps/
9 (diabetic adj3 amputat*).tw.
10 exp Debridement/
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11 (debrid* or slough* or deslough*).tw.
12 or/1-11
13 exp Negative-Pressure Wound Therapy/
14 exp Suction/
15 exp Vacuum/
16 exp Drainage/
17 (negative pressure or negative-pressure or TNP).tw.
18 (sub-atmospheric or subatmospheric).tw.
19 ((seal* adj surface*) or (seal* adj aspirat*)).tw.
20 (wound adj2 suction*).tw.
21 ((foam adj suction) or (suction adj dressing*)).tw.
22 (vacuum assisted closure or VAC).tw.
23 ((vacuum adj therapy) or (vacuum adj dressing*) or (vacuum adj seal*) or (vacuum adj closure) or (vacuum adj compression) or
(vacuum adj pack*) or (vacuum adj drainage) or (suction* adj drainage)).tw.
24 or/13-23
25 12 and 24
26 randomized controlled trial.pt.
27 controlled clinical trial.pt.
28 randomi?ed.ab.
29 placebo.ab.
30 clinical trials as topic.sh.
31 randomly.ab.
32 trial.ti.
33 or/26-32
34 exp animals/ not humans.sh.
35 33 not 34
36 25 and 35
Ovid Embase
1 exp foot ulcer/
2 exp diabetic foot/
3 (diabet* adj3 ulcer*).tw.
4 (diabet* adj3 (foot or feet)).tw.
5 (diabet* adj3 wound*).tw.
6 (diabet* adj3 defect*).tw.
7 exp amputation/
8 exp amputation stump/
9 (diabetic adj3 amputat*).tw.
10 exp debridement/
11 (debrid* or slough* or deslough*).tw.
12 or/1-11
13 exp vacuum assisted closure/
14 exp suction drainage/
15 exp vacuum/
16 exp wound drainage/
17 (negative pressure or negative-pressure or TNP).tw.
18 (sub-atmospheric or subatmospheric).tw.
19 ((seal* adj surface*) or (seal* adj aspirat*)).tw.
20 (wound adj2 suction*).tw.
21 ((foam adj suction) or (suction adj dressing*)).tw.
22 (vacuum assisted closure or VAC).tw.
23 ((vacuum adj therapy) or (vacuum adj dressing*) or (vacuum adj seal*) or (vacuum adj closure) or (vacuum adj compression) or
(vacuum adj pack*) or (vacuum adj drainage) or (suction* adj drainage)).tw.
24 or/13-23
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25 12 and 24
26 Randomized controlled trials/
27 Single-Blind Method/
28 Double-Blind Method/
29 Crossover Procedure/
30 (random* or factorial* or crossover* or cross over* or cross-over* or placebo* or assign* or allocat* or volunteer*).ti,ab.
31 (doubl* adj blind*).ti,ab.
32 (singl* adj blind*).ti,ab.
33 or/26-32
34 exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/
35 human/ or human cell/
36 and/34-35
37 34 not 36
38 33 not 37
39 25 and 38
EBSCO CINAHL Plus
S39 S25 AND S38
S38 S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR S37
S37 TI allocat* random* or AB allocat* random*
S36 MH “Quantitative Studies”
S35 TI placebo* or AB placebo*
S34 MH “Placebos”
S33 TI random* allocat* or AB random* allocat*
S32 MH “Random Assignment”
S31 TI randomi?ed control* trial* or AB randomi?ed control* trial*
S30 AB ( singl* or doubl* or trebl* or tripl* ) and AB ( blind* or mask* )
S29 TI ( singl* or doubl* or trebl* or tripl* ) and TI ( blind* or mask* )
S28 TI clinic* N1 trial* or AB clinic* N1 trial*
S27 PT Clinical trial
S26 MH “Clinical Trials+”
S25 S12 AND S24
S24 S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23
S23 AB ( ((vacuum therapy) or (vacuum dressing*) or (vacuum seal*) or (vacuum closure) or (vacuum compression) or (vacuum pack*)
or (vacuum drainage) or (suction* drainage)) ) OR TI ( ((vacuum therapy) or (vacuum dressing*) or (vacuum seal*) or (vacuum closure)
or (vacuum compression) or (vacuum pack*) or (vacuum drainage) or (suction* drainage)) )
S22 TI ( (vacuum assisted or vacuum-assisted or VAC) ) OR AB ( (vacuum assisted or vacuum-assisted or VAC) )
S21 TI ( ((foam n1 suction) or (suction n1 dressing*)) ) OR AB ( ((foam n1 suction) or (suction n1 dressing*)) )
S20 TI (wound n2 suction*) OR AB (wound n2 suction*)
S19 TI ( ((seal* n1 surface*) or (seal* n1 aspirat*)) ) OR AB ( ((seal* n1 surface*) or (seal* n1 aspirat*)) )
S18 TI ( (sub-atmospheric or subatmospheric) ) OR AB ( (sub-atmospheric or subatmospheric) )
S17 TI ( (negative pressure or negative-pressure or TNP) ) OR AB ( (negative pressure or negative-pressure or TNP) )
S16 (MH “Drainage+”)
S15 (MH “Vacuum”)
S14 (MH “Suction+”)
S13 (MH “Negative Pressure Wound Therapy”)
S12 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11
S11 TI ( debrid* or slough* or deslough* ) OR AB ( debrid* or slough* or deslough* )
S10 (MH “Debridement+”)
S9 TI (diabetic n3 amputat*) OR AB (diabetic n3 amputat*)
S8 (MH “Amputation Stumps”)
S7 (MH “Amputation+”)
S6 TI (diabet* n3 defect*) OR AB (diabet* n3 defect*)
S5 TI (diabet* n3 (wound*)) OR AB (diabet* n3 (wound*))
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S4 TI ( (diabet* n3 (foot or feet)) ) OR AB ( (diabet* n3 (foot or feet)) )
S3 TI (diabet* n3 ulcer*) OR AB (diabet* n3 ulcer*)
S2 (MH “Diabetic Foot”)
S1 (MH “Foot Ulcer+”)
US National Institutes of Health Ongoing Trials Register (ClinicalTrials.gov)
(diabetic OR diabetes OR “foot ulcer”) AND (“negative pressure” OR NPWT OR TNP OR vacuum assisted OR VAC)
World Health Organization International Clinical Trials Registry Platform
(diabetic OR diabetes OR “foot ulcer”) AND (“negative pressure” OR NPWT OR TNP OR vacuum assisted OR VAC)
Appendix 2. Cochrane tool for assessing risk of bias
1. Was the allocation sequence randomly generated?
Low risk of bias
The investigators describe a random component in the sequence generation process such as: referring to a random number table; using
a computer random number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots.
High risk of bias
The investigators describe a non-random component in the sequence generation process. Usually, the description would involve some
systematic, non-random approach, for example: sequence generated by odd or even date of birth; sequence generated by some rule
based on date (or day) of admission; sequence generated by some rule based on hospital or clinic record number.
Unclear
Insufficient information about the sequence generation process is provided to permit a judgement of low or high risk of bias.
2. Was the treatment allocation adequately concealed?
Low risk of bias
Participants and investigators enrolling participants could not foresee assignment because one of the following, or an equivalent
method, was used to conceal allocation: central allocation (including telephone, web-based, and pharmacy-controlled randomisation);
sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes.
High risk of bias
Participants or investigators enrolling participants could possibly foresee assignments and thus introduce selection bias, such as allocation
based on: use of an open random allocation schedule (e.g. a list of random numbers); assignment envelopes without appropriate
safeguards (e.g. envelopes were unsealed, non-opaque, or not sequentially numbered); alternation or rotation; date of birth; case record
number; any other explicitly unconcealed procedure.
Unclear
Insufficient information is provided to permit a judgement of low or high risk of bias. This is usually the case if the method of
concealment is not described, or not described in sufficient detail to allow a definitive judgement, for example if the use of assignment
envelopes is described, but it is unclear whether envelopes were sequentially numbered, opaque, and sealed.
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3. Blinding: was knowledge of the allocated interventions adequately prevented during the study?
Low risk of bias
Any one of the following:
• No blinding, but the review authors judge that the outcome and the outcome measurement are not likely to be influenced by
lack of blinding.
• Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.
• Either participants or some key study personnel were not blinded, but outcome assessment was blinded, and the non-blinding of
others unlikely to introduce bias.
High risk of bias
Any one of the following:
• No blinding or incomplete blinding, and the outcome or outcome measurement is likely to be influenced by lack of blinding.
• Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken.
• Either participants or some key study personnel were not blinded, and the non-blinding of others likely to introduce bias.
Unclear
Either of the following:
• Insufficient information to permit judgement of low or high risk of bias.
• The study did not address this outcome.
4. Were incomplete outcome data adequately addressed?
Low risk of bias
Any one of the following:
• No missing outcome data.
• Reasons for missing outcome data are unlikely to be related to true outcome (for survival data, censoring unlikely to be
introducing bias).
• Missing outcome data are balanced in numbers across intervention groups, with similar reasons for missing data across groups.
• For dichotomous outcome data, the proportion of missing outcomes compared with the observed event risk is not enough to
have a clinically relevant impact on the intervention effect estimate.
• For continuous outcome data, a plausible effect size (difference in means or standardised difference in means) among missing
outcomes is not enough to have a clinically relevant impact on the observed effect size.
• Missing data have been imputed using appropriate methods.
High risk of bias
Any one of the following:
• Reasons for missing outcome data are likely to be related to the true outcome, with either an imbalance in numbers or reasons
for missing data across intervention groups.
• For dichotomous outcome data, the proportion of missing outcomes compared with the observed event risk is enough to induce
clinically relevant bias in the intervention effect estimate.
• For continuous outcome data, a plausible effect size (difference in means or standardised difference in means) among missing
outcomes is enough to induce a clinically relevant bias in the observed effect size.
• ’As-treated’ analysis done with a substantial departure of the intervention received from that assigned at randomisation.
• Potentially inappropriate application of simple imputation.
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Unclear
Either of the following:
• Insufficient reporting of attrition/exclusions to permit a judgement of low or high risk of bias (e.g. number randomised not
stated, no reasons for missing data provided).
• The study did not address this outcome.
5. Are reports of the study free of suggestion of selective outcome reporting?
Low risk of bias
Either of the following:
• The study protocol is available and all of the study’s prespecified (primary and secondary) outcomes that are of interest in the
review have been reported in the prespecified way.
• The study protocol is not available, but it is clear that the published reports include all expected outcomes, including those that
were prespecified (convincing text of this nature may be uncommon).
High risk of bias
Any one of the following:
• Not all of the study’s prespecified primary outcomes have been reported.
• One or more primary outcomes is/are reported using measurements, analysis methods, or subsets of the data (e.g. subscales) that
were not prespecified.
• One or more reported primary outcomes was/were not prespecified (unless clear justification for their reporting is provided, such
as an unexpected adverse effect).
• One or more outcomes of interest in the review is/are reported incompletely so that they cannot be entered in a meta-analysis.
• The study report fails to include results for a key outcome that would be expected to have been reported for such a study.
Unclear
Insufficient information is provided to permit a judgement of low or high risk of bias. It is likely that the majority of studies will fall
into this category.
6. Other sources of potential bias
Low risk of bias
The study appears to be free of other sources of bias.
High risk of bias
There is at least one important risk of bias. For example, the study:
• had a potential source of bias related to the specific study design used; or
• has been claimed to have been fraudulent; or
• had some other problem.
Unclear
There may be a risk of bias, but there is either:
• insufficient information to assess whether an important risk of bias exists; or
• insufficient rationale or evidence that an identified problem will introduce bias.
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WH A T ’ S N E W
Last assessed as up-to-date: 10 January 2018.
Date Event Description
30 January 2018 New citation required and conclusions have changed Six additional studies included in the review and conclu-
sions changed
23 January 2018 Amended Two studies previously awaiting classification have been
moved to excluded studies
23 January 2018 New search has been performed First update: new search.GRADE assessment of certainty
of the evidence undertaken and methodology updated.
ZL joined the author team
H I S T O R Y
Protocol first published: Issue 1, 2013
Review first published: Issue 10, 2013
Date Event Description
3 June 2014 Amended Edits to table labels
C O N T R I B U T I O N S O F A U T H O R S
Zhenmi Liu: co-ordinated the review update; extracted data; checked the quality of data extraction; analysed or interpreted data;
undertook and checked quality assessment; performed statistical analysis; checked the quality of the statistical analysis; produced the
first draft of the review update; contributed to writing or editing the review update; advised on the review update; secured funding;
performed previous work that was the foundation of the current review update; wrote to study authors, experts and companies;
performed economic analysis; performed translations; approved the final review update prior to submission; and is a guarantor of the
review update.
Jo Dumville: conceived the review; designed and co-ordinated the review update; extracted data; checked the quality of data extraction;
analysed or interpreted data; undertook and checked quality assessment; checked the quality of the statistical analysis; contributed to
writing or editing the review update; advised on the review update; secured funding; performed previous work that was the foundation
of the current review update and approved the final review update prior to submission.
Robert Hinchliffe: co-ordinated the review update; advised on the review update; performed previous work that was the foundation of
the current review update and approved the final review update prior to submission.
Nicky Cullum: co-ordinated the review update; advised on the review update; performed previous work that was the foundation of the
current review update and approved the final review update prior to submission.
Fran Game: co-ordinated the review update; advised on the review update; performed previous work that was the foundation of the
current review update and approved the final review update prior to submission.
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Nikki Stubbs: co-ordinated the review update; advised on the review update and performed previous work that was the foundation of
the current review update.
Michael Sweeting: co-ordinated the review update; advised on the review update and performed previous work that was the foundation
of the current review update.
Frank Peinemann: co-ordinated the review update; advised on the review update and performed previous work that was the foundation
of the current review update.
Contributions of editorial base
Joan Webster (Editor): edited the review and the update, advised on methodology, interpretation and content and approved the final
version for publication.
Sally Bell-Syer and Gill Rizzello (Managing Editors): co-ordinated the editorial process. Advised on interpretation and content. Edited
the review and the update respectively.
Ruth Foxlee and Naomi Shaw (Information Specialists): designed and edited the search strategy, edited the methods section and ran
the searches for the review and update respectively.
Rachel Richardson (Methodologist): edited the review.
Ursula Gonthier (Editorial Assistant): edited the Plain language summary and the reference sections.
D E C L A R A T I O N S O F I N T E R E S T
Zhenmi Liu: my employment at the University of Manchester was supported by a grant from the National Institute for Health Research
(NIHR) UK (NIHR Systematic Review Fellowships).
Jo Dumville: received research funding from the National Institute for Health Research (NIHR) UK for the production of systematic
reviews focusing on high priority Cochrane Reviews in the prevention and treatment of wounds. This research was co-funded by the
NIHR Manchester Biomedical Research Centre and partly funded by the National Institute for Health Research Collaboration for
Leadership in Applied Health Research and Care (NIHR CLAHRC) Greater Manchester.
Robert Hinchliffe: none known.
Nicky Cullum: received research funding from the National Institute for Health Research (NIHR) UK for wounds-related research
and systematic reviews focusing on high priority Cochrane Reviews in the prevention and treatment of wounds. This research was
co-funded by the NIHR Manchester Biomedical Research Centre and partly funded by the National Institute for Health Research
Collaboration for Leadership in Applied Health Research and Care (NIHR CLAHRC) Greater Manchester.
Fran Game: grant funding was provided to Derby Teaching Hospitals NHS FT for a researcher led, NHS sponsored trial into a
device for wound healing for the diabetic foot by the manufacturer of the device, Reapplix ApS Denmark. Grant funding was also
provided to Derby Teaching Hospitals NHS FT for an investigator led, NHS sponsored trial into wound healing, using Omnigen by
the manufacturers of the product, NuVision.
Nikki Stubbs: has received payments for Cogora, a healthcare marketing agency and expenses for conference attendance. She has
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S O U R C E S O F S U P P O R T
Internal sources
• Division of Nursing, Midwifery and Social Work, School of Health Sciences, Faculty of Biology, Medicine and Health,
University of Manchester, UK, UK.
External sources
• National Institute for Health Research (NIHR), UK.
This project was supported by the NIHR, via Cochrane Infrastructure and Cochrane Programme Grant funding (NIHR Cochrane
Programme Grant 13/89/08 - High Priority Cochrane Reviews in Wound Prevention and Treatment) to Cochrane Wounds. The
views and opinions expressed herein are those of the authors and do not necessarily reflect those of the Systematic Reviews
Programme, the NIHR, the NHS or the Department of Health.
• NIHR Manchester Biomedical Research Centre (BRC), UK.
This research was co-funded by the NIHR Manchester BRC. The views expressed in this publication are those of the authors and not
necessarily those of the NHS, the National Institute for Health Research or the Department of Health.
• National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care (NIHR CLAHRC),
Greater Manchester, UK.
Nicky Cullum and Jo Dumville’s work on this project was partly funded by the NIHR CLAHRC, Greater Manchester. The funder
had no role in the decision to publish, or preparation of the manuscript. However, the review may be considered to be affiliated to the
work of the NIHR CLAHRC Greater Manchester. The views expressed herein are those of the authors and not necessarily those of
the NHS, NIHR or the Department of Health.
• National Institute for Health Research (NIHR) Systematic Review Fellowships (NIHR-RMFI-2015-06-52 Zhenmi Liu), UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We have populated sections of the ’Methods’ and ’Discussion’ which were previously not available in the older version of Review
Manager as follows: Assessment of reporting biases; Overall completeness and applicability of evidence.
Description of the condition: we added additional information to the ’Background’ section.
Types of outcome measures: we removed ’change (and rate of change) in wound size’ as this is not ’complete wound healing.’ We
also made a post hoc decision to assess ’cost-effectiveness’ rather than ’resource use.’ This is an important outcome from both clinical
and practical perspective and negative pressure wound therapy (NPWT) is used widely but very expensive. We also added ’number of
wounds closed or covered with surgery’ and ’time to closure or coverage surgery’ as secondary outcomes as they are clinically relevant
outcomes, differing from the outcome of ’complete wound healing.’
Summary of findings: we decided to downgrade when the ’Risk of bias’ assessment for selection bias or blinding was unclear. We also
added these outcomes: number of wounds closed or covered with surgery; adverse events; cost-effectiveness and wound recurrence to
the ’Summary of findings’ tables.
Due to the new included studies which included various types of dressings, we carried out a post hoc subgroup analysis based on the
type of dressings.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Amputation; ∗Bandages; ∗Wound Healing; Debridement; Diabetic Foot [∗surgery]; Negative-Pressure Wound Therapy [adverse
effects; ∗methods]; Randomized Controlled Trials as Topic
MeSH check words
Humans
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